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PREFACE 
This dissertation explores missed opportunities in identifying and managing patients 
presenting with Tuberculosis symptoms. Quite often emphasis is placed on increasing 
demand for services. But how often do patients present to a qualified health professional and 
are missed or frustrated and forced to leave before being attended to? Whether right or wrong 
it, I have always argued that the supply side of healthcare needs more attention especially in 
developing countries. After all, word about an excellent service will get out quickly! Equally 
poor service will force patients to seek care elsewhere even if the health facility in question is 
nearer to them than alternatives. Unlike other diseases, diagnosis and treatment of TB early 
in the illness is critical to stopping transmission. I am particularly interested in streamlining 
TB care pathways as part of the innovative ways to eliminate it. Investigating why having 
efficacious protocols may not necessarily translate into efficient TB care has added another 
dimension to my understanding of process improvement. Hopefully I can make a humble 
contribution to the end TB agenda   with the skills acquired during this research.  
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Background: Timeliness of Tuberculosis (TB) treatment is critical to stopping its 
transmission and preventing disease complications and death. Efficiency in identifying and 
treating presumptive TB cases is critical to reducing delays.  
Aims: We determined the association between health service-related factors and delays in 
initiating TB treatment within primary care settings in Uganda. Perspectives of healthcare 
workers on practices underlying healthcare facility level delays were also described.  
Methods: A mixed methods study was conducted based on facility-register records of 1199 
treated TB cases and key informant interviews with 27 outpatient staffs. Health service-
related factors (size, ownership, number of laboratory personnel, diagnostic technology used 
for diagnosis, sequencing of TB tests and timing with the week of the lab test) were fitted 
into a linear regression model to identify predictors of TB care process durations and to 
identify predictors of treatment delay. Qualitative data was analyzed for themes related to 
healthcare workers’ observations and experiences regarding facility level delays. 
Results: Median total time for treatment initiation was two days with median time for 
laboratory results turnaround and for initiating treatment each being one day. Independent 
predictors of prolonged TB care processes were a weekend laboratory visit (ẞ=0.36, 95%CI 
0.11, 0.60) and retesting after an index negative result (ẞ=1.17, 95%CI 0.64, 1.69) for 
laboratory turnaround time; and diagnosis by Gene Xpert test (ẞ=0.39, 95%CI 0.07 0.71) 
and having a repeat test irrespective of index result ((ẞ=0.51, 95%CI 0.08, 0.93) if index 
result was negative, and (ẞ=0.26, 95%CI 0.06, 0.45) if positive). Factors that increased 
likelihood of prolonged TAT and or TxIT were weekend lab visit 2.06(1.49, 2.84), diagnosis 
by Xpert test (aOR 1.79, 95% CI 1.04, 3.10) and repeat testing [aOR 3.49, 95%CI 1.81, 6.75] 
if index result is negative and [aOR 1.81, 95%CI 1.27, 2.60] if positive). Healthcare workers 
observed that presumptive TB cases were kept in queues alongside other patients, and staff 
had a negative attitude to TB patients despite knowing recommended timesaving TB care 
procedures.  
Conclusion: Factors increasing risk of healthcare facility level delay were related care 
procedures more than a healthcare facility’s structure.  Despite knowing recommended 
procedures that minimize delays, healthcare workers report several challenges hampering 
implementation of protocols.   
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BACKGROUND 
In 2015 the End TB Agenda was launched with an ambitious goal of reducing global 
annual Tuberculosis (TB) incidence to less than 10 cases per 100,000 population and TB 
related deaths to zero by 2035 (WHO, 2015). To achieve this, there must be a precipitous 
decline in TB levels in the high TB burden countries (HBCs) in Africa and South East Asia. 
In 2015, Uganda’s TB burden was 202 new TB cases per 100,000 population (WHO, 2016); 
which is 20 times the 2035 target. The case for strengthening healthcare systems in TB 
control is twofold. First, strong healthcare systems will result into optimal use of current TB 
control interventions (Chiang et al, 2013). Further, a strong healthcare system is needed to 
maximize incremental effects of the much-needed new TB-related medical technologies (Lin, 
Dowdy, Dye, Murray, & Cohen, 2012). Assessing how current TB control interventions are 
being delivered is therefore a crucial step in transforming the epidemic. 
Treatment of symptomatic cases is central to TB control as this stops transmission 
and prevents adverse disease outcomes simultaneously, unlike other interventions. Because 
most new TB cases arise from recent transmission, as opposed to reactivation of dormant 
infection, scaling up treatment alone can substantially reduce TB incidence (Dye & Williams, 
2010). This involves patients initiating treatment and adhering to a multiple drug protocol for 
at least six months. Bottlenecks in diagnosis and initiation of effective medication continue to 
undermine the population level impact of this TB control strategy. In 2016, Uganda reported 
a case detection rate of 55% but a treatment completion rate of 73% (WHO, 2016).  
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Therefore besides its being an entry point, urgent attention to problems surrounding initiation 
of treatment is dictated by a poor case detection.  
National programs do not routinely track proportions of TB cases starting treatment 
late during the illness (Marais and Raviglione, 2010). Significant transmission and mortality 
can still occur if most TB cases are treated late in the illness. Improving the count of TB 
cases initiated on treatment must therefore go along with efforts to minimize delays in care 
seeking and also within healthcare facilities (HFs).  However, there are differences in 
definitional criteria for TB treatment delay, making it difficult to reliably estimate its extent 
(Finnie et al, 2011). Also it is not clear how much healthcare system factors contribute to 
delays, compared to patient-related ones. This lack of crucial information may hamper 
consideration of TB care related delays among quality improvement priorities. But access to 
definitive TB care has substantially expanded in most of the HBCs (MoH, 2012; WHO, 
2013), which calls for increased attention to quality of TB care being provided within HFs 
with TB services.   
Problem statement 
Most TB programs in HBCs, including Uganda, depend on TB patients’ self – 
reporting for consultation before they are identified and treated (Yuen et al, 2015). 
Considerable time is therefore lost before disease symptoms are serious enough to warrant 
seeking health care (Ho, Fox & Marais, 2016). When there are HF-level delays in identifying 
and treating patients with TB symptoms, additional time is lost before effective treatment is 
eventually initiated. In addition, experience(s) of delay while receiving care also shape 
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subsequent decisions about seeking care at a particular HF or related ones. Long wait and 
process turnaround times are major underlying factors for patients shunning publicly owned 
HFs and yet these are the majority TB services outlets. Even after a patient has an initial 
consultation, prior experience of delay increases risk of non-adherence to follow up 
appointments and eventually loss to follow up (MacPherson et al, 2014). Thus, HF level 
delays not only increase the time of the HF phase of TB care but may also negatively affect 
care-seeking behavior.  
Within a HF, delay may be in identifying and referring presumptive TB cases for 
testing, completing the required tests, receiving results, or initiating treatment for those with 
disease. Several service delivery factors causing delays at any one of these steps have been 
described in TB care literature. These relate to adherence to treatment protocols (Davis et al, 
2011); use of antibiotics and other symptom suppressants (Rabin et al 2013); behavior of 
healthcare workers (Chimbatata, Zhou, Chimbatata, & Xu, 2017); and diagnostic 
technologies (Yuen et al, 2015). Also, quality of care literature has consistently raised 
weekend effect to highlight problems faced by patients after hours (Bray et al, 2016). In 
Uganda there are efficacious TB treatment protocols that are mandated nationally (MoH, 
2017a; MoH, 2017b). A key question is whether they are being adhered to. Another aspect is 
whether delays differ among the types of HFs. Besides type of ownership, Uganda’s HFs are 
organized in a hierarchy depending on daily patient load and number and type of staff skills 
and available technologies. Publicly-owned HFs may differ significantly from non-profit 
private ones. Knowing the differences among HF types helps to decide whether the problem 
of delays requires tailored solutions. 
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Justification of the study 
 From a health systems angle, it is important to understand the relationship of service 
delivery factors with delay in initiating treatment within HFs accredited for TB services. 
Existing literature on HF level delays has many limitations, which diminishes its value to 
quality improvement initiatives. Most studies are based on patient interviews limiting detail 
of care procedures since patients have limited comprehension of technical processes. Also by 
design, most studies do not distinguish between HFs providing TB care from those that are 
not. This makes it difficult to tailor interventions to HFs that are providing TB care as a one-
stop service. A study design that addresses the above two major weaknesses within existing 
literature is necessary to understand the problem of delays in the context of expanding access 
to TB services.  
A study undertaken from the perspective of healthcare workers allows for a more 
comprehensive list of service delivery factors to be studied. Existing records provide a data 
source from which verifiable details of care processes can be obtained at  minimal cost. In-
depth interviews with healthcare workers provide an opportunity for personnel to describe 
the real-life context of the TB care initiation process and suggest ways to improve it. Also 
through interviews, one can understand various work-arounds in response to existing 
challenges in TB care. 
 Specific aims and hypotheses 
This study’s  goal was to examine the association between service delivery factors 
and timeliness of Tuberculosis treatment initiation within accredited primary care facilities in 
5 
 
Uganda. Service delivery factors are characteristics relating to HF structure (ownership, 
geographical location, level within health system hierarchy, number of laboratory personnel), 
and care delivery (number of prescreening visits, diagnostic technology used, two specimen 
testing, use of antibiotics, and weekend specimen submission).   
The specific aims and hypotheses were: 
Aim-1: To explore the association between service-delivery factors (structural and care 
delivery characteristics) and TB care process times (laboratory turnaround time and treatment 
initiation time) 
Aim 1 part 1: Measure the association between service delivery factors and laboratory 
turnaround time (time from submission of specimens to reporting of results) 
 Hypothesis 1: Service delivery factors increase laboratory turnaround time 
Aim 1 part 2: Measure the association between service delivery factors and treatment 
initiation time (time from reporting of results to initiation of treatment) 
Hypothesis 2: Service delivery factors increase treatment initiation time 
Aim 2: Measure the association between service delivery factors and Tuberculosis treatment 
initiation delay 
Hypothesis: Service delivery factors have delay Tuberculosis treatment initiation 
Aim 3: Describe perspectives of healthcare workers (heads of OPD, clinical teams and 
laboratory services) on delays within selected health facilities providing Tuberculosis 
services. 
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Review of relevant literature  
 A major concern about current TB control efforts is that expansion in service 
coverage has not translated into a substantial decline in TB levels. By 2013, there were 
reports of substantial expansion in access to free TB care across most of the high TB burden 
countries (WHO, 2013).  But decline in TB incidence has stagnated at 1.5% annually 
compared to a projection of 5-10% necessary to significantly impact the epidemic by 2020 
(WHO, 2015). TB is now the number one cause of infectious disease mortality ahead of HIV; 
and is among the top 10 contributors to all-cause mortality (GBD 2015 Mortality and Causes 
of Death Collaborators, 2016).   
There are calls for superior technologies but some counter that a lot more can be 
achieved with existing ones, especially in developing countries where economic constraints 
disfavor diffusion of technology (Chiang, Van Weezenbeek, Mori, & Enarson, 2013). Across 
south Asia, for example, there were substantial differences in TB burden despite using 
comparable technologies for diagnosis and treatment (Onozaki et al., 2015). A strong health 
system environment free of delays is important to optimizing use of existing tools and 
maximizing the incremental effect of new ones (Lin, Dowdy, Dye, Murray, & Cohen, 2012). 
Thus, it is important to understand how health systems in an environment of expanded access 
is affecting progress towards TB elimination.  
Literature review will be limited to high burden countries for relevance to the study 
setting. This is in four sections. First is the relevance of treatment to TB control. We then 
discuss the effect of health systems on timely initiation of TB treatment. We then review 
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literature on the association of service delivery factors with health system -level delays. 
Finally, we review factors related to the observed practices among healthcare workers 
involved in TB care.   
Contribution of treatment to Tuberculosis control 
Global control efforts aim to stop TB transmission while simultaneously improving 
outcomes of those with disease (Onozaki & Raviglione, 2010). Each year there are close to 
10 million new symptomatic TB cases worldwide (WHO, 2016). In addition, it is estimated 
that one-fifth of the world’s population has latent TB infection, which under conditions of 
immune compromise may be reactivated, progressing into symptomatic disease (Dye, 
Scheele, Dolin, Pathania, & Raviglione, 1999). Therefore, eradication requires tackling these 
two facets of TB (Rangaka et al., 2015). However, the global focus currently is on 
elimination, which creates room for decisions on which facets to tackle to quickly reduce TB 
levels to a set benchmark.  
Prioritization of Tuberculosis control interventions  
The current TB control goal is to reduce annual disease incidence to below 10 
incident case per 100,000 population globally by 2035 (WHO, 2015). Over 90% of prevalent 
TB cases are new as opposed to chronic ones (Chiang et al., 2013). Further, these new cases 
are mostly from recent infection arising from symptomatic cases as distinct from reactivation 
of latent TB (Dye & Williams, 2010). So most of the TB burden is due to incident cases 
arising from recent transmission. Accordingly, an intervention that significantly reduces 
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transmission can turnaround the TB epidemic since this accounts for most of the prevalent 
cases.  
The options for TB control have for decades remained limited to treatment of 
symptomatic cases to affect cure, prevention therapy to eradicate latent infection, and use of 
the BCG vaccine (Marais et al., 2010). The biological action of the BCG vaccine currently in 
use is limited to only preventing progression into severe disease, but it does not stop 
development of symptomatic disease following exposure to TB bacilli (Marais et al., 2010). 
Between the other two options, treatment is rated higher than prevention therapy because of 
the much higher contribution to disease incidence by symptomatic cases relative to latent 
infection. A patient with pulmonary TB becomes non-infectious within two weeks of 
initiating treatment (Brooks, Lassiter, & Young, 1973; Rouillon, Perdrizet, & Parrot, 1976).  
Further, only treatment regimens have adequate drug doses to eradicate bacilli in a 
symptomatic TB case and thus improve clinical outcomes. Hence treatment is the best TB 
control strategy as it has the simultaneous action of stopping transmission and TB levels and 
preventing adverse outcomes. 
Significance of treatment initiation in Tuberculosis control  
TB treatment currently involves at least six months of an intensive drug regimen. A 
key question is how is initiation of treatment temporally related to stopping transmission and 
prevention of adverse disease outcomes? Without treatment, a single TB case will result in 
10 to 15 additional cases per year and up to 16-23 new infections over the three-year natural 
history of the disease (Dye & Williams, 2010). Following initiation of treatment, majority of 
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TB patients become noninfectious within two weeks (Rouillon et al., 1976). This brings to 
the fore the importance of treatment early to minimize transmission. Also associated with 
early treatment is a potential cost saving on care seeking that accounts for most of the high 
TB related costs currently reported in HBCs (Abimbola et al., 2015; Tanimura, Jaramillo, 
Weil, Raviglione, & Lonnroth, 2014). Hence the milestone of treatment initiation is a turning 
point in transmission and economic costs of the disease especially if initiated early in the 
illness.  
Beyond initiation of treatment, however, a longer period of effective treatment is 
needed to prevent disease complications and death. Mortality, sequelae and disease 
recurrence is higher among patients who discontinue treatment than those who complete TB 
treatment (Kolappan, Subramani, Karunakaran, & Narayanan, 2006). Furthermore, 
discontinuation of treatment increases the risk of developing resistance. Most of the cases of 
multi-drug resistant TB occur among patients treated that never completed their course of 
treatment. Therefore, in terms of relevance of treatment initiation, a lot can be gained if 
treatment is early in the disease, but these gains can be reversed if patients do not complete 
the treatment course. In this case the milestone is critical as an entry point since the 
population level impact of treatment ultimately depends on what proportion of  prevalent TB 
cases are on effective medications.  
It is important that most prevalent TB cases are initiated on treatment to improve TB 
incidence and related mortality.  Unfortunately, the regular case reporting process cannot be 
used as an accurate measure of performance because most countries exclude diagnosed TB 
patients who are not initiated on treatment (Harries, Rusen, Chiang, Hinderaker, & Enarson, 
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2009). This includes Uganda’s national TB control program (MoH, 2017c). Reporting only 
treated TB cases serves to emphasize linking diagnosis to effective treatment. In 2015, 
Uganda reported a TB case detection rate (CDR) of 55% (WHO, 2016). This represents the 
proportion of prevalent TB cases that were treated and therefore effectively removed from 
the infectious pool. Exclusion of untreated cases underestimates true case detection and case 
fatality, and also over estimates treatment success. Addressing delays and LTFU therefore 
helps narrow the gap between treatment initiation and true CDR leading to a more accurate 
measurement of TB program performance.  
Health systems and timeliness of Tuberculosis treatment  
The main approach to providing TB services is by integrating TB diagnosis and 
treatment into primary care in HBCs, in contrast to setting up stand-alone TB clinics. This 
means effective delivery of TB services is dependent upon a strong health system functioning 
well in all locations and all primary care services (Cazabon et al., 2017). However, what 
constitutes a start point for the health system remains unclear especially regarding the setting 
where care is provided (MacKian, 2003). Here we describe care destinations to which 
patients with symptoms suggestive of TB may present for consultation.  
Conceptual issues on health systems and TB control  
  Studies on TB care seeking differ in how they identify the start point of a health 
system. In a systematic review, Finnie et al (2011) noted that what constituted a health 
system varied among different authors. Some defined this as any facility with a professional 
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with training in modern medicine while others restricted themselves to settings with both 
diagnosis and treatment onsite.  
The WHO’s six building blocks describe desirable attributes of a health system for it 
to achieve a desired health outcome (WHO, 2007). These are: numbers and skills of 
healthcare workers, medical logistics and technologies, leadership and governance, health 
management information systems (HMIS), financing, and service delivery. With regard to 
TB services, health systems strengthening (HSS) mainly aims to increase access to services, 
improve quality and reduce financial burden (WHO, 2016). In integrating TB services into 
primary care in Uganda, the minimum requirements are use of standardized treatment and 
HMIS protocols, trained personnel, steady stock-levels of medicines and laboratory supplies, 
and providing services at no charge (MoH, 2012). At a minimum, HSS efforts aim to 
improve referrals to HFs with definitive diagnostic TB diagnostic services. Developing 
countries have mushrooming private clinics and other small medical outlets where 
consultation for most illnesses is first sought and yet their capacity to provide TB services is 
questionable (Cazabon et al., 2017).  Therefore, these present a gap as far as HSS for TB 
services is concerned.  
Effect of health systems on timeliness of Tuberculosis treatment initiation  
The period from the onset of symptoms up to the point of initiation of TB treatment in 
most literature is divided into patient and health system phases (Cai et al., 2015; Finnie et al., 
2011; Li et al., 2013; Sreeramareddy, Qin, Satyanarayana, Subbaraman, & Pai, 2014; Storla, 
Yimer, & Bjune, 2008). The former is when a patient with TB symptoms is seeking care, and 
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the latter after he or she has presented for consultation. There is heterogeneity in defining the 
start point for the health system phase and accordingly it is difficult to compare durations of 
the two phases (Finnie et al., 2011). Even studies which compared the same start point, 
different cut off thresholds were used to decide whether a patient experienced delay or not 
differ. The resulting difficulty in comparing the two phases to each other, and the individual 
phases among studies makes it impossible to decide which phase to prioritize to minimize 
time to initiation of TB treatment. Studies that define the health system phase as starting 
when a patient consults with an accredited TB care provider generally report a shorter health 
system phase (Takarinda et al., 2015). Those that disregard presence of TB services at the 
start point generally report a longer health system phase because they take referral between 
providers into consideration (Makwakwa, Sheu, Chiang, Lin, & Chang, 2014). In Angola a 
much shorter health system phase was observed because of efficient referral of presumptive 
cases by non-accredited providers. Nevertheless, it is important to consider any time lost 
after a patient has presented for consultation as a missed opportunity that should be 
prevented.  
 Besides its relative contribution to the time  before treatment initiation, health 
systems also influence health-seeking behavior. Characteristics of the health system shape 
acceptability and subsequent decisions on utilization of services (MacKian, 2003). 
Convenience of working hours, poor experience with professionals, perceived poor quality of 
services and requirement for multiple visits have often been cited in explaining delays in 
consulting with TB service providers (Cai et al., 2015; Finnie et al., 2011; Li et al., 2013; 
Storla et al., 2008). In Angola, delay in care seeking care at a HF with TB services or 
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returning for follow up was higher among patients who rated services poorly based on 
opening hours, waiting time and attitude of health workers (Segagni Lusignani et al., 2013). 
Similar reasons related to the health system partly explained why patients were lost to follow 
up (LTFU) even after a diagnosis of TB had been established (MacPherson et al., 2014). A 
national service survey in Uganda found that only 46% of the population rated services in 
public facilities as good (UBOS, 2016). But majority of TB cases are currently being treated 
in government facilities (Cazabon et al., 2017); demonstrating need to engage the private 
sector to increase odds of a presumptive case engaging with a source of definitive care early 
in the illness.  
The above two contributions of the health system to timeliness of TB treatment are 
amplified by the fact that resource constraints in HBCs hamper efforts to screen at risk 
groups before they seek care (Yuen et al., 2015). In waiting for TB patients to self-report for 
consultation before they are identified and managed, a lot of time is already lost when the 
patient reaches a HF with TB services. Under such circumstances minimizing delays not only 
cuts the total time to treatment but also shapes a patient’s perception of quality and 
subsequent utilization of services. 
Service delivery factors and health system level delays  
The basis for TB treatment protocols is to minimize delays in identifying patients for 
TB testing, completion of tests and initiation of treatment (TBCARE 1, 2014).  Emphasis is 
on same day physician turnaround of laboratory results and initiation of treatment (Davis et 
al., 2012). Among the plethora of studies on delays within the health system, a number of 
issues standout regarding measurement of delays and the multilevel factors affecting delays.  
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Measurement of health system level delays  
  Most studies measure delays as a binary outcome but in a few, this was reported as a 
time to event outcome. The former report a proportion of patients whose time to event 
exceeds a cutoff threshold. Some of the recent studies in Africa highlight several issues in 
describing the magnitude of health system delays as shown in Table 1. 
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Table 1: Summary of recent studies on health system level delays in Africa 
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Most studies on health system level delays were based on patient interviews. Each 
study measured both care seeking (patient phase) and the health system phase. Reporting on 
the health system phase was limited to the total duration of time; none of the studies 
attempted to compare door to diagnosis and diagnosis to treatment initiation times. The 
duration of the health system phase varied considerably from 7 to 62 days and respective 
interquartile ranges that varied from 4 days in Ethiopia (Bogale, Diro, Shiferaw, & Yenit, 
2017) to 120 days in Mozambique (Saifodine et al., 2013) . Most of the studies used a 14-day 
cut off threshold in defining health system level delays. The proportion of patients 
experiencing delays more than 2 weeks ranged from 47.8 to 68.7% in those studies that 
included all forms of TB and less than 26% where patients with a microbiological diagnosis 
were studied.    
Measurement criteria may make it impossible to compare health system level delays 
across studies and geographical settings.  Finnie et al (2011) observed that the start point for 
the health system varied among different studies. In Zimbabwe and Angola, only contact 
with a TB service provider was considered part of the health system phase, and as such fewer 
patients experienced health systems delays compared to those non-accredited providers who 
were considered part of the health system phase (Saifodine et al., 2013; Takarinda et al., 
2015). Furthermore, although most of these studies defined health system level delay as 
exceeding 14 days, variability in cut off thresholds has also been previously reported (Finnie 
et al., 2011). Finnie et al (2011) observed that most studies take into consideration whether 
the provider offered TB services when defining the health system phase of TB care. There is 
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limited literature excluding provider-provider referrals and thus measuring delay within 
health facilities accredited to provide both diagnosis and treatment in a single stop. Even in 
Angola where a very short duration of the health system phase was reported, this was 
attributed to efficiency of the referral network rather than most patients having consulted first 
at a HF providing TB services (Segagni Lusignani et al., 2013). 
Association of service delivery factors with health facility delays 
Care cascade models provide a framework to visualize and systematically analyze the 
different care steps leading to a desired care endpoint, in our case initiation of TB treatment. 
The WHO developed a model to help improve TB case detection by analyzing steps along 
the TB care cascade up to the point of treatment initiation (WHO, 2011). The figure below is 
adapted from the section corresponding to care steps between arrival for consultation and 
initiation of TB treatment. 
Figure 1: Care pathway between arrival for consultation and TB treatment initiation  
18 
 
 
From the above framework, service delivery factors associated with delays primarily 
relate to identification of patients for TB testing, completing required tests and initiating 
those with disease on treatment. In addition, a mechanism that traces and returns patients 
missing follow up could also substantially reduce treatment delays.  
The WHO recommends systematic screening of all patients in HFs for TB in settings 
with HIV prevalence of 5% or more (WHO, 2015b). At the level of screening, ideally all 
patients presenting with TB symptoms should be identified and referred for testing on their 
index visit. But studies in HBCs in Africa show that patients make multiple visits to the same 
provider before they are eventually diagnosed (Bogale et al., 2017; Takarinda et al., 2015). In 
Tanzania, 50% of TB patients were diagnosed after more than three times seeking care from 
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the same provider even though they had clear TB defining symptoms (Said et al., 2017). In a 
study among primary care facilities providing TB services in Uganda, only 20% of patients 
with cough lasting more than two weeks were referred for TB testing (Davis et al., 2011). 
Apart from the direct effect of LTFU and prolonging time to eventual diagnosis and 
treatment, inefficiencies in the screening process also increase costs of care to the patient.  
At the level of diagnosis, the current standard is to confirm disease diagnosis and 
immediately initiate treatment basing on a single positive sputum test (TBCARE 1, 2014). 
But some HFs require a second test before an individual is eventually diagnosed.  Five to 
eight percent of TB patients are diagnosed on a repeat test the following day after the initial 
test. Further, microscopy will diagnose only 50% of TB cases that are positive when Gene 
Xpert is used. In Peru, 42% of TB patients required repeat clinical encounters having 
previously tested negative on microscopy (Bailey et al., 2011). Additional literature from 
Africa has also reported patients who initially test negative  thus taking longer before a 
definitive diagnosis was made (Belay, Bjune, Ameni, & Abebe, 2012; Gebreegziabher et al., 
2016; Makwakwa et al., 2014). Therefore, at the level of establishing the diagnosis of TB, the 
type of technology contributes to delay through required repeat visits for testing or return 
after initially testing negative.  
Violation of good clinical and laboratory practices by personnel can also lead to 
prolonged delays. Fast tracking of services for patients with TB symptoms through shorter 
wait times and laboratory TAT are essential for TB control (WHO, 2009). Chaisson et al 
(2015) attributes unnecessary repeat testing, late reporting of laboratory results and poor 
patient hand offs to non-adherence to standard operating procedures (Chaisson et al., 2015). 
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In Angola, long waiting times were associated with health facility level delays (Segagni 
Lusignani et al., 2013). Violations of operating procedures are common under conditions of 
heavy workload and late or weekend presentation for consultation (Bray et al., 2016). 
Besides throughput time, a large part of laboratory TAT is contributed to by adherence to 
standard operating practices (Chauhan, Trivedi, Patel, Gami, & Haridas, 2014). Therefore, 
even with use of faster and more accurate technologies such as Gene Xpert, treatment delays 
may still occur due to poor practices by healthcare workers.   
A system to trace missing patients and return them to care is a mechanism through 
which delays and LTFU could be reduced. In looking at HIV care, Hallet et al (2013) 
proposed a side door into the care cascade to account for patients who are lost temporarily 
but return at later steps of the care pathway. Absence of pre-appointment and default 
reminder systems have been reported to have a positive correlation with prolonged delays in 
returning for follow up and LTFU. Some HF interventions, for example giving antibiotics, 
may undermine adherence to appointment time and expectations by providing temporary 
relief of symptoms (Wang et al., 2011; Yimer, Holm-Hansen, Storla, & Bjune, 2014). In 
settings with inadequate mechanisms to enforce prescription drug regulations, use of 
antibiotics may provide temporary relief of symptoms (Wang et al., 2011). Thus, at the 
structural level, lack of a system to track missed visits may exacerbate delays in confirming a 
diagnosis or initiating those with disease on treatment.  But during the process of providing 
care, relief of symptoms through antibiotics may cause treatment delay.  
Besides factors that relate to the care cascade, there are structural factors that may 
impact health facility level delays. Characteristics of the health facility where the patient first 
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consults for TB related symptoms have been reported to increase delays in diagnosis. For 
example, unaccredited HFs fail to identify and refer patients with TB symptoms for definitive 
diagnosis and treatment (Makwakwa et al., 2014; Segagni Lusignani et al., 2013). At the 
level of HFs with TB services, ownership of the health facility and its ranking within the 
health system have been reported to have a causal association with delays. Delays have been 
reported to occur more among TB patients diagnosed in privately-owned facilities compared 
to publicly-owned ones (Belay et al., 2012). Regarding ranking in the health system 
hierarchy, some studies report more delays are at smaller  health centers, like health clinics, 
(Bogale et al., 2017; Gebreegziabher, Bjune, & Yimer, 2016a) while others find this occurs 
more at district and tertiary hospitals (Saifodine et al., 2013).   
Existing studies examining health system level delays focused on facility structural 
characteristics (Storla et al, 2008; Finnie et al, 2011). This is probably because they are based 
on patient interviews, which limits details about care processes. An analysis of the care 
cascade offers an opportunity to identify and analyze process factors. Subsequently a wide 
array of health service delivery factors that include structural and process ones should be 
studied and their importance in TB care understood.  
Personnel characteristics and health facility level delays  
Personnel are a building block for health systems and are thus critical to delivery of 
TB services (WHO, 2007). Integration of TB diagnosis and treatment into primary care 
means that personnel should be able to integrate identification and management of 
presumptive TB cases into their work routines. 
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Human resources and TB treatment in primary care settings 
Developing countries have often faced deficiencies in numbers and skills of 
healthcare workers due to brain drain amidst increased need to meet demands for 
decentralized health services (Dovlo, 2004). Task-shifting has accordingly taken center stage 
in plugging these human resource gaps with outcomes comparable to those with 
internationally recognized counterparts (Dovlo, 2004). In most primary care settings, most 
services are provided by medical assistants and enrolled nurses who have taken on 
responsibilities of medical doctors and registered nurses. It therefore follows that TB services 
are mostly provided by mid-level healthcare workers. 
In addition to pre-service education, mid-level healthcare workers often are trained to 
be task-oriented with  standard operating procedures (SOPs) for providing services. In 
Uganda, for example, SOPs are simplified and standardized, which is essential to 
overcoming skill limitations amongst mid-level healthcare workers (MoH, 2017a; MoH, 
2017b). In such seemingly good work environments one needs to understand how personnel 
link to timeliness of TB care. 
Personnel characteristics and TB treatment delay 
Practices among healthcare workers are the major link between personnel and TB 
treatment delay.  This is in form of communication between service points and activities in 
identifying presumptive TB cases, ordering and conducting diagnostic tests, providing results 
to patients, and linking those with disease to treatment (Storla et al, 2008). Significant gaps 
between knowledge levels and practices in managing patients have cast doubt on adequacy of 
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training in improving practices of healthcare workers (Grimshaw et al., 2001). Therefore, it is 
important to develop theory-based interventions to address knowledge and other 
determinants of behavior concurrently. A critical task however is to identify practices among 
healthcare workers that these theory-based interventions may address. 
Practices that need to be addressed to prevent delays come from observation and 
intervention studies along the TB care cascade. In an observational study in Uganda, Davis et 
al (2011) attributed low rates of referral for TB testing, completion of TB testing and 
initiation of treatment to poor adherence to standard operating procedures [SOPs]. Chaisson 
et al (2015) and Manabe et al (2015) attributed didactic training and on-site mentorship to 
better adherence to SOPs and feedback among healthcare workers to  improvements in TB 
case detection and treatment. Feedback enabled healthcare workers to analyze performance 
and identify areas for improvement (Chaisson et al., 2015). Further, a study in Malawi found 
that treatment delays often stemmed from efforts by healthcare workers to handle  heavy 
workloads (Chimbatata, Zhou, Chimbatata, & Xu, 2017). Often healthcare workers gave 
priority to more urgent cases leading to delays in attending to patients with presumptive TB 
cases. In summary therefore, personnel practices leading to treatment delay relate to 
adherence to SOPs, dealing with a heavy workload and limited performance feedback. 
Conceptual framework 
The conceptual framework for this study was based on the WHO framework for 
increasing TB case detection (Onozaki & Raviglione, 2010) and the Donabedian model 
(Donabedian, 1988). These two frameworks provided us with a frame to visualize the 
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associations between system and process factors and the outcome of treatment initiation. The 
Donabedian model links  structure, process and outcome to  show how  health system factors 
relateto timing of TB treatment initiation. The WHO framework is a pathway to care model 
describing two ways to realize early TB case detection. The first is a patient-initiated 
pathway in which a patient with TB symptoms self-reports to a health facility for 
consultation. Being diagnosed early during the illness depends on a patient’s ability to 
recognize TB symptoms and knowing where to seek care; access to high quality health care 
services; sufficient capacity of the health facility to identify those who should be tested for 
TB; providing quality-assured diagnostic testing; and a well-functioning referral system. The 
second is a screening pathway in which the TB care provider traces and screens close 
contacts of TB cases and other at-risk individuals who have not yet sought care or have 
initiated the patient pathway but are not adherent. The patient-initiated pathway is most 
relevant to this study since the recommended approach to identifying TB  is by screening 
patients within HFs. This encompasses the section of the screening pathway concerning 
patients initiating the patient pathway but are not adherent.  
For the purposes of this study, applicable steps were identification of patients for TB testing, 
the process of testing for TB onsite by microscopy or Xpert test, referral for treatment 
initiation within the health facility. From the literature review, several factors related to 
characteristics of the health facility, care delivery and personnel were identified as 
contributing to timing of TB treatment as indicated in Figure 2 below: 
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Figure 2: Conceptual model of service delivery factors related to treatment delay  
 
 
Public health significance  
The goal of this study was to deepen understanding of delays in identifying and managing 
presumptive TB cases within Ugandian healthcare facilities accredited to provide TB 
services. These are missed opportunities to prevent transmission, improve individual 
outcomes and cut TB related costs. This is particularly important in the current context of the 
current global agenda of eliminating TB by 2035 requiring multi-pronged efforts to 
accelerate TB control. Delay being a measure of the quality dimension of timeliness makes 
study findings even more important in identifying areas for improvement in TB care, and by 
extension the primary care setting within which TB services are integrated. Understanding 
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service delivery factors from the perspective of the provider especially, through qualitative 
interviews, is important in prioritizing areas for intervention. 
In contributing to the literature needed to minimize missed opportunities in initiating TB 
treatment, this study’s findings contribute to reducing controversies in reporting of untreated 
TB cases. Diagnosed patients that remain untreated at the time of reporting are excluded 
from case notification, which underestimates case detection and overestimates positive 
treatment outcomes. Getting all diagnosed TB cases treated on time avoids such scenarios 
and gives an accurate and complete picture of TB program performance.  
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MATERIALS AND METHODS 
Study design  
The goal of this study was to examine the association between service delivery 
factors and timeliness of Tuberculosis treatment initiation within primary care facilities. 
Service delivery factors were characteristics relating to the HF’s structure (ownership, 
geographic location, level within health system hierarchy, number of laboratory personnel), 
and its care delivery processes (number of prescreening visits, diagnostic technology used, 
two specimen testing, use of antibiotics, and weekend specimen submission). 
The specific aims were: 
Aim-1: Explore the association between service-delivery factors (structural and care delivery 
characteristics) and TB care process times (laboratory turnaround time [TAT] and treatment 
initiation time) 
Aim 1a: Measure the association between service delivery factors and laboratory turnaround 
time (time between submission of specimen for testing and reporting of test results) 
Hypothesis 1: service delivery factors increase laboratory turnaround time 
Aim 1b: Measure the association between service delivery factors and treatment initiation 
time (time between results reporting and initiation of treatment) 
Hypothesis 2: service delivery factors increase treatment initiation time 
Aim 2: Measure the association between service delivery factors and Tuberculosis treatment 
initiation delay 
Hypothesis: service delivery factors delay Tuberculosis treatment initiation 
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Aim 3: Describe perspectives of healthcare workers (in-charges of OPD, heads of clinical 
teams and heads of laboratories) on delays within selected health facilities providing 
Tuberculosis services. 
A mixed methods design comprising of a retrospective cohort study using existing TB 
care records and a case study involving in-depth interviews with healthcare workers was 
used. Mixed methods is important in understanding complex interactions among a health 
system’s components (Ozawa & Pongpirul, 2014). In this case the qualitative component was 
necessary to understand practices of personnel providing TB care.  A case study design is 
suitable as the phenomenon (actions of personnel) needs to be studied in the real-life context 
(Carolan, Forbat, & Smith, 2016).   
Study setting  
The study was conducted in the districts of Kabarole, Kasese and Kyenjojo in mid-
western Uganda shown in the map (Figure 3).  
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Figure 3: Location of study districts in Uganda  
 
Source: Uganda Bureau of statistics, 2016 
Here HFs are organized in a hierarchy by size of the catchment population and 
available scope of services. Primary care HFs comprise of hospitals and, below this, different 
levels of health centers while tertiary care comprises of regional and national referral 
hospitals. Unlike tertiary hospitals that under direct control of the central government , the 
work of primary care facilities are under district local governments that oversee planning and 
provision of services in line with policies and care standards set by the central government.. 
All HFs with a functional laboratory (district hospitals, and levels IV and III health centers 
[HCs]) are eligible for accreditation to provide TB diagnosis and treatment. Catchment 
populations for the different HF levels are 30,000 people for a level three Health Center 
(HCIII); 100,000 people for a level four Health Center (HCIV); and 300,000-500,000 people 
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for a district hospital. Each HF level has a defined staffing standard with technical teams 
headed by medical officers at HCIVs and district hospitals, and medical clinical officers at 
HCIIIs.  
TB care is provided free of charge as an outpatient service across all publicly owned and 
non-profit HFs. Each of these HFs provide diagnostic testing through microscopy or Gene 
Xpert (Xpert). A mechanism also exists for certain categories of presumptive TB patients to 
have their specimens referred for a more advanced Xpert test if microscopy is negative or 
drug resistance is suspected. Laboratory services are supported by an external and internal 
quality assurance system run by the national TB reference laboratory. Decisions on treatment 
are based on nationally mandated protocols. A decision to start TB treatment is based on 
either laboratory confirmation of the diagnosis or clinical grounds. The protocol recommends 
treatment be initiated at the HF where diagnosis is made before a request to transfer to 
another HF is considered.  
In the period January 2016 to June 2017, the three districts accounted for 59.9% of the 
diagnosed TB cases in the region; 60% in 2016 and 57.9% in 2017 respectively.  
Table 2: Tuberculosis case load from January 2016 to June 2017  
DISTRICT  
Number of 
Health Facilities 
2016 
2017       
(up to June) 
Total 
Kabarole* 34 565 239 804 
Kasese 33 338 168 506 
Kyenjojo 18 303 135 438 
TOTAL 
85 1206 542 1748 
* Approximately 45-50% of TB cases are diagnosed at the regional referral hospital  
(Source: Mid-Western Zonal TB and Leprosy program office) 
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QUANTITATIVE COMPONENT (AIMS 1&2)  
Study design  
The association between service delivery factors (structural and care delivery 
characteristics) and process time (aim 1) and that between service delivery factors time and 
TB treatment (aim 2) were assessed using existing care records for patients with laboratory 
confirmed TB from January 1st, 2016 to December 31st, 2017. This start point was chosen 
because this is the time when most of the current TB care data capture tools were introduced.  
Study population 
The study population was TB cases within the districts of Kabarole, Kasese and 
Kyenjojo in Western Uganda diagnosed using either microscopy or Xpert test, which are the 
recommended laboratory tests for diagnosis of TB in primary care settings (MoH, 2017a). 
The study excluded TB patients diagnosed using radio imaging or on clinical grounds since 
these are not the gold standard for diagnosis. 
Sampling frame, sample selection and sampling strategy 
The sample frame comprised of all laboratory confirmed TB cases diagnosed at 
accredited HFs within the three districts during the period January 1st, 2016 to December 31st, 
2017. Data for all TB patients with a positive microscopy or Xpert test were screened for 
eligibility. Patients who were not diagnosed and initiated on TB treatment at the same study 
site were excluded. This included patients diagnosed after referral of specimens for Gene 
Xpert and other advanced diagnostic tests; patients transferred in or out of the HF before 
starting    These are patients among whom exogenous causes of delay that are associated with 
referral could not be excluded.  
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 A purposive multi-stage sampling approach was used in which the top three high TB 
burden districts in the region (Kabarole, Kyenjojo and Kasese) were selected for data 
collection. In each district, all laboratory confirmed TB cases in any HFs providing single 
stop TB diagnosis and treatment were included. 
Data sources 
Existing data on TB care was obtained from the district health office registry and TB 
care registers. Each district health office registry has a paper-based register that contains 
information about all HFs operating in the district in terms of ownership, geographic 
location, level within the health system hierarchy, and staffing levels. This registry was 
updated by the district health officer whenever licensure for new services, changes in 
personnel and opening of new HFs occurred. 
TB care registers are nationally standardized, paper-based records. There are two 
main registers: laboratory sputum register and unit’s TB register. Patient information is 
entered into these registers at all TB care service points within a HF. Each register has an 
illustrated set of instructions to guide healthcare workers’ entering records. Only the Ministry 
of Health (MoH) reviews and revises the registers. Full or obsolete registers are be securely 
archived within the records department stores in each HF. The table below describes 
information entered about each TB patient in each of the two HF registers and facility 
information in the district register. This information entered in the registers had not 
significantly changed among the different versions of the registers in use since 2016. 
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Table 3: Data Elements in Each Tuberculosis Care Register   
Register  Place of 
deployment  
Purpose/description   TB care related information**   
Laboratory 
register  
Laboratory   Registry of patients 
submitting sputum for 
TB testing including 
samples referred to a 
central laboratory 
 Sputum specimen submission date 
 Diagnostic test used 
(Microscopy/Xpert) 
 Number of specimens tested  
 Test results for each specimen  
 HIV status 
 Patient sociodemographic 
characteristics- name, age, sex  
Unit TB 
register  
Pharmacy/ HF 
dispensary  
 Registry of patients 
treated for TB at HF 
including transfers-in 
 Results reporting date 
 Treatment initiation date 
 Previous TB treatment history 
 Patient sociodemographic 
characteristics- name, age, sex  
District 
health 
office 
registry  
District health 
office  
 Record of HFs and 
staff deployment in the 
district 
 HF name and ownership 
 Level within health system hierarchy  
 District name 
 Number of personnel by cadre 
** Up to the point of treatment initiation 
Quarterly unit TB register data is reported by the district TB supervisor who transfers this 
information from all HFs into the district TB master register. The district register was used to 
check for missing information in the laboratory and treatment registers on sociodemographic 
variables and care dates.   
Measurements and instruments 
Individual patient data start and end points were sputum submission date and initiation of TB 
treatment respectively. The sputum submission date was when a patient visited the lab for 
testing and his/her personal details were entered in the laboratory sputum register. Initiation 
of treatment date was when the TB patient was issued a treatment card and dispensed his/her 
first dose of anti-Tuberculosis medicines, which was entered in the unit TB register..  
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Study variables were derived or computed from TB care related information in the 
clinical registers or district health office registry. Three key TB care milestone dates -- 
specimen submission, results reporting and treatment initiation -- were used to compute the 
following time related variables as shown in Figure 4 below:  
Figure 4: Timeline diagram for Tuberculosis treatment initiation  
 
  From the above timeline diagram, three time related variables were computed:  
  Total treatment time – interval in calendar days between specimen submission and 
initiation of treatment ([initiation of treatment date minus specimen submission date] 
+1)  
 Laboratory turnaround time- interval in calendar days between submission of sputum 
specimen to the laboratory and reporting of the diagnosis ([resulting reporting date 
minus first sputum sample submission date]+1) 
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 Treatment initiation time interval in calendar days between reporting of the diagnosis 
and initiation of treatment ([treatment initiation minus resulting reporting  date]+1) 
The primary outcome was treatment delay. This was measured by dichotomizing 
treatment delay as more than two calendar days, and no delay if less. This cut off threshold 
was based on ISTC guideline, which recommends same-day physician TAT of laboratory TB 
results and initiation of treatment (TBCARE1). A two-day threshold allowed for patients 
who needed a repeat test having initially tested negative on the first specimen. All study 
measures were categorized as outcome process or structure measures depending on the 
component of the Donabedian model they best describe as shown in the table below:  
Table 4: Categorization of study variables  
Variable category Measured variable 
Outcome  
Timeliness of TB treatment 
initiation 
Treatment delay  
Process  
Process time  Laboratory TAT  
Treatment initiation time 
Structure   
Health facility characteristics  Ownership, geographic(district) location, level within 
health system hierarchy, and number of laboratory 
personnel  
Care delivery characteristics  Technology used for diagnosis, Use of antibiotics prior to 
diagnosis, Number of pre-diagnosis visits, Use of two 
specimens for diagnosis, and Submission of a TB 
specimen on a weekend 
Patient characteristics  Name, age, sex, previous history of TB and HIV status 
The above variables are dependent or independent variables, or co-variates depending on the 
aim being assessed as shown in the measurement matrices below:    
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Table 5: Measurement matrix (aims 1a & 1b) 
Measured variable Data source(s) Definition Variable type 
Dependent variables     
Laboratory Turnaround time (1a) Laboratory register, 
Unit TB register 
Time interval in days between specimen submission and 
results reporting dates 
Continuous 
Treatment initiation time (1b) Unit TB register Time interval in days between results reporting and 
treatment initiation dates  
Continuous 
Independent variables     
Health facility characteristics     
Health facility Ownership District registry Health facility affiliation Categorical (Public/Private) 
HF Level   District registry Ranking of HF within health system hierarchy  Categorical (HCIII/ 
HCIV/district hospital) 
Number of laboratory personnel Laboratory reports  Sub-grouping of unduplicated number of  laboratory 
personnel on duty register during study period  
Categorical   
Geographic location  Laboratory register District location of HF  Categorical  
Service delivery characteristics     
Weekend specimen submission Laboratory register Specimen submission date on a Friday, Saturday or Sunday  Categorical (Yes/No) 
# specimens tested Laboratory register Number of specimens tested during diagnostic episode  Categorical  (1,2 or 3) 
Lab test sequence  Laboratory register  Order  of tests conducted  Categorical (single or repeat) 
Covariates    
Patient characteristics    
Age Laboratory register Years  Continuous  
Sex Laboratory register Male/Female Categorical (Male/Female) 
HIV status  laboratory register  Documented HIV status   Categorical (positive/ negative) 
Previous history of TB treatment Treatment register TB treatment prior to current diagnosis episode  Categorical (yes/No) 
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Table 6: Measurement matrix (aim 2)  
Measured variable Data source(s) Definition Variable type 
Dependent variable     
Treatment delay Lab & Unit TB registers  > 3 days between sputum submission and treatment dates Categorical (Yes/No) 
Independent variables     
Health facility characteristics     
Health facility Ownership District registry Health facility affiliation Categorical (Public/Private) 
HF Level   District registry Ranking of HF within health system hierarchy  Categorical (HCIII/ 
HCIV/district hospital) 
Number of laboratory personnel Laboratory reports  Sub-grouping of unduplicated number of  laboratory 
personnel on duty register during study period  
Categorical (1-2,3-4 & 5+)  
Geographic location  Laboratory register District location of HF  Categorical 
(Kasese/Kabarole/Kyenjojo) 
Service delivery characteristics     
Weekend specimen submission Laboratory register Specimen submitted  on a Friday, Saturday or Sunday  Categorical (Yes/No) 
# specimens tested Laboratory register Number of specimens tested during diagnostic episode  Categorical (1,2 or 3) 
Lab test sequence  Laboratory register  Order  of tests conducted  Categorical(single/repeat)  
Covariates    
Patient characteristics    
Age Laboratory register Years  Continuous  
Sex Laboratory register Male/Female Categorical (Male/Female) 
HIV status  laboratory register  Documented HIV status   Categorical(positive/negative)   
Previous history of TB treatment Treatment register TB treatment prior to current diagnosis episode  Categorical (yes/No) 
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Sample size and power calculation  
We used known estimates of TB cases over the study period to compute power to 
detect significant difference among hospitals, level four Health centers (HCIVs) and level 
three Health centers (HCIIIs). These are the three different levels within the health system 
hierarchy that provide TB services.  We estimated a two year total TB case load of 240 
patients among hospitals, 150 among HCIVs and 720 among HCIIIs as summarized in Table 
7 below:  
Table 7: Estimated sample size by health facility level  
Health facility 
level 
Number of 
Health 
Facilities 
Average # TB 
cases   
Total 
Hospital  6 40 240 
HCIV 5 30 150 
HCIII 72 10 720 
TOTAL 
85  1,110 
Based on the above estimated totals for each HF, we determined the power to detect 
significant difference in treatment delay between district hospitals and HCIVs. A study in 
Zimbabwe found 20.5% delay at district hospitals compared to 37.6% at health centers 
(Takarinda et al, 2015).  
Power estimation was computed using OpenEpi version 3, version three based on a formula 
for cohort studies.  
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Using the above estimates of delays as a guide and with TB cases at HCIV as exposed group 
(150) and those among hospitals as non-exposed (240), risk ratio of delays between the two 
groups was used to compute power of the study as shown in table 8 below:   
Table 8: Power estimation for the study 
 
Parameter  Input data  
Confidence interval (%)  95 
Number of exposed (TB cases at HCIV level) 150 
Risk of delay among exposed  37.6 
Number of non-exposed (TB cases at Hospital level) 240 
Risk of disease among non-exposed 20.5 
Risk ratio  1.8 
Power (based on normal approximation)  96.15 
 
Therefore, a sample size involving 150 TB cases at HCIV and 240 at hospital level 
had power of 96.15% to detect significant differences in delay at the two levels as shown in 
table 8.   
 
Data collection and management 
Data abstraction: Data was abstracted from TB care registers for the period between January 
1st 2016 and December 31st, 2017 by trained research assistants using paper abstraction forms 
(appendix ii). At each HF, all registers were collected at a central point before data 
abstraction commenced. Assisted by HF record assistants, research assistants identified each 
patient in the laboratory register that had a positive microscopy or Gene Xpert result and 
followed him or her into the treatment register.  With exception of a HCIII that lacked a 
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laboratory register for the period January 1st to July 25th, 2016, each HF had both registers. 
For six confirmed TB patients in another HCIII however, corresponding records in the 
treatment register were missing. These six patients were assumed not to have started TB 
treated and thus were excluded since there was no evidence of them ever being started on 
treatment. 
 Starting with the laboratory register all patients with one or more positive Xpert or 
microscopy test results were identified and screened for study eligibility. After abstraction of 
relevant study information each patient was then traced through the unit treatment register. 
Each study subject had an individual abstraction form for recording all relevant information 
across the two TB care points. Four patients whose laboratory records lacked a specimen 
submission date were excluded because they lacked a critical study start point. 
Sociodemographic characteristics were concordant between the two registers except for a 
few instances where last names were used to determine a patient’s missing gender.  
Data on HF’s structure (ownership, geographical location, level within health system 
hierarchy and number of laboratory personnel) was collected from the district health office 
registry using a health facility data extraction form (appendix ii). Abstracted data from the 
district health office registry was then confirmed with the health facility in-charge officer at 
the time of obtaining consent to conduct research. Periods of drug stock outs were recorded 
at each facility from stock cards and contrasted with each patient’s results reporting date to 
establish whether diagnosis was made during outage of drugs or not.  
Data storage: The principal investigator checked filled abstraction forms for accuracy and 
completeness daily. Repeat facility visits were conducted to make necessary corrections and 
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collect missing data. All collected data was stored in a filing cabinet in a room only 
accessible by the principal investigator. Electronic data was stored in folders on a password-
protected computer and encrypted mobile devices.  
Reliability and validity of measurements:  The following activities were conducted to 
improve accuracy and inter-rater reliability of study findings:  
- Training of research assistants by the principal investigator that also included practice 
sessions 
- Pilot testing of data collection tools for content, flow and clarity as well as acceptability 
- Daily review of collected data for accuracy and completeness  
- Repeat site visits to correct data 
- Quality assurance check conducted by principal investigator by randomly selecting 5% 
of the study subjects, re-abstracting their TB care information and comparing it to 
information already collected by research assistants.  
Data analysis  
The unit of analysis was a patient with laboratory confirmed TB basing on a Gene 
Xpert or microscopy test. Data for each study subject was entered in epi-Data version 7 and 
exported into STATA version 15 (College Station, TX USA) for analysis.  
Descriptive statistics were summarized using frequencies and counts for categorical 
data; and means (SD) and medians (IQR) for continuous variables as appropriate. Findings 
were displayed in frequency tables. A complete case analysis approach in which patients with 
missing records are excluded was used.   Multiple regression models were used to test 
hypotheses in both aims 1 and 2. 
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Independent variables with p-value >0.25 at univariate analysis were excluded during 
multivariable regression. Selection of factors for the final model was done using a backward 
–forward stepwise approach for both aims 1 and 2. Predictors with p-value<0.15 and those 
with known scientific relation to the outcome were then retained in the final model. A level 
of 5% was used to assess statistical significance of predictor variables.   
To test the association between service-delivery factors and process time, structural 
and care delivery factors were fitted in a multiple linear regression model while controlling 
for patient characteristics. In this case the primary outcomes were continuous variables 
(Turnaround time (TAT) for aim 1a and treatment initiation time (TIT) for aim 1b).  
The baseline statistical model for aim 1 was:  
Y = ẞ0 + ẞ1HF1 + …. + ẞ4 HF4 + ẞ5CD1 +…+ ẞ8 CD4 + ẞ9PC1+…. +ẞ12 PC4 +Ꜫ 
Where:  
Y = process time (Turnaround time [TAT] for aim 1a or Treatment initiation time 
[TIT] for aim 1b) 
ẞ0- ẞ13= coefficients for model variables  
HF1-HF4 = Health facility characteristics (Ownership, Geographical location, level 
within health system hierarchy, and number of laboratory personnel) 
CD1-CD4= Care delivery characteristics (diagnostic technology used, number of 
specimens tested, sequence of tests and weekend lab visit) 
PC1-PC4= Patient characteristics (age, sex, HIV status, previous history of TB 
treatment) 
The analysis matrices for aims 1aand 1b are summarized below: 
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Table 9: Analysis matrix for study aim 1  
 #Aim 1a #Aim 1b 
Hypothesis  Service delivery factors increase 
laboratory turnaround time 
Service delivery factors increase 
treatment initiation time  
Dependent 
variable(s)  
Turnaround time (TAT) Treatment initiation time (TXIT) 
 
Independent 
variables 
 
 
Service delivery factors  
- Health facility characteristics 
[HF] 
- Care delivery characteristics 
Service delivery factors  
- Health facility 
characteristics [HF] 
- Care delivery 
characteristics CD] 
Covariates  Patient characteristics [PC]  (age, 
gender, HIV status, previous TB 
treatment)  
 Patient characteristics [PC] 
(age, gender, HIV status,  
previous TB treatment)  
Statistical 
approach  
Linear regression  Linear regression  
Estimate  Coefficient  Coefficient  
Level of 
significance,α  
5% 5% 
For aim 2, we used multiple logistic regression model since the primary outcome 
(treatment delay) was a binary categorical outcome defined as 1= treatment delay and 0= no 
treatment delay. The final logistic regression model controlled for patient characteristics. All 
the service delivery factors were tested using a single model shown below:  
Logit (TD) = ẞ0 + ẞ1HF1 + …. + ẞ4 HF4 + ẞ5CD1 +…+ ẞ8 CD4 + ẞ9PC1+…. +ẞ12PC4  
Where:  
TD = treatment delay (treatment delay = 1 & no treatment delay =0) 
ẞ0- ẞ13= coefficients for model variables  
HF1-HF4 = Health facility characteristics (Ownership, Geographical location, level 
within health system hierarchy, and number of laboratory personnel) 
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CD1-CD4= Care delivery characteristics (Diagnostic technology used, number of 
specimens tested, sequence of tests and weekend lab visit) 
PC1-PC4= Patient characteristics (age, sex, HIV status, previous history of TB 
treatment) 
Parameters were estimated using odds ratios (OR) as shown in the analysis matrix below: 
Table 10: Analysis matrix for aim 2  
 #Aim 2 
Hypothesis  Service delivery factors will delay initiation of Tuberculosis treatment 
Dependent variable(s)  Treatment delay [TD](delay =1 & no delay =0) 
 
Independent variables 
 
 
 Service delivery factors  
(Health facility characteristics [HF] & 
Care delivery characteristics [CD]) 
Covariates  Patient characteristics [PC] (age, gender, HIV status,  previous TB 
treatment) 
Statistical approach  Logistic regression  
Estimate  Odds Ratio (OR); and 95%CI OR 
Level of significance,α  5% 
QUALITATIVE COMPONENT (AIM 3) 
Study design 
In-depth interviews with three representatives from a sample of HF in one district (in-
charge of OPD, head of clinical team and head of laboratory services) were conducted. 
Specifically, the respondents were interviewed by the principal investigator on the causes of 
TB treatment delay and how this should be addressed based on what they routinely did or had 
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observed. Field and interview notes including descriptions of care process flow maps were 
also collected to supplement data collected during interviews.   
Study population  
The study population comprised of all in-charges of OPD, heads of clinical teams and 
heads of laboratories in the region. These were key positions in the provision of out-patient 
services including TB diagnosis and treatment. Appointments to these positions of 
responsibility is by the HF in charge, usually based on seniority within the department or 
unit. In-charges of OPD are usually registered nurses while heads of clinical teams are either 
medical officers or medical clinical officers. Heads of labs vary from technologists in HCIVs 
and hospitals to technicians in HCIIIs.   
Sampling, sample size and recruitment  
Interviews were conducted from health facilities in Kabarole district; the district with the 
highest number of TB cases in the region and therefore likely to have more healthcare 
workers with experience managing TB.  Respondents were from the top nine HFs serving 
populations at very high risk of TB -- populations from tea plantations, fishing villages and 
slum areas. If the selected respondent was unable to participate, a replacement was selected 
from the same health facility according to the hierarchy since these individuals would stand 
in for absent team leaders.  
Measurements and instruments 
 The study aimed at eliciting perspectives of healthcare workers on delays based on 
their experience and observations within HFs that were continuously providing TB services. 
Respondents described and explained practices in identifying presumptive TB cases and 
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completing subsequent care steps that led to delays.  Available qualitative literature discusses 
TB treatment delay within the context of implementing recommended infection control 
procedures (Buregeya et al, 2013; Chimbatata et al, 2017).  The proposed themes and codes 
from this angle relate to institutional and personnel factors such as knowledge of TB care 
best practices and benefits of using protocols, attitude towards TB patients and even 
healthcare workers caring for them (Chimbatata et al, 2017) . Other factors were professional 
attitude to work and concerns and fears in caring for TB patients and available measures to 
address those (Buregeya et al, 2013). In other literature staff expressed concern about 
perceptions of others’ support to TB patients (courtesy stigma) especially TB patients whose 
care falls outside work routines and for which health workers are not rewarded (Link and 
Phelan, 2006; Philips et al , 2011). Table 11 shows the pre-selected themes and codes were:  
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Table 11: Measurement matrix for aim 3 
family  Themes/code groups  Explanation  
Knowledge of 
risks & benefits  
Infection control  Measures necessary to prevent 
transmission of TB within HFs  
Stigma among staff about  
attending to TB patients (courtesy 
stigma) 
Dishonor or disgrace associated 
with being responsible for 
treating TB patients  
Protection for healthcare workers Measures to prevent healthcare 
workers from getting infected 
with TB 
Barriers to 
implementing 
protocols 
Volume of workload  Number of patients attended to 
by a healthcare worker on a 
working day  
Acceptability   Attitude towards use of TB 
treatment protocols  
Knowledge of protocols  Ability to describe treatment 
protocol and  explain why it is 
established  
Quality of support by external 
technical teams 
Rating of support supervisory 
visits by district and national TB 
teams  
Organizational 
culture 
Ranking of TB care on task 
priority list as per described 
specimen handling schedules  
Stigma / discrimination  
Shared care decision making Involvement of patients in 
making care decisions  
TB task specialization  TB care tasks allocated to 
specific individuals in HF 
Reward and punishment system 
of the organization 
Feedback system on task 
performance  
Management of missed visits Mechanisms to trace patients 
who miss appointments 
Work 
environment 
safety 
Availability of safety equipment Masks, sputum testing cabinets  
TB in healthcare workers  Incidents of TB among 
healthcare workers  
Safety concerns   Poor infrastructure set up-space 
and ventilation 
Work ethics Attendance to duty Absenteeism, neglect of duty   
Adherence to good clinical/lab 
practice  
Violations of standard practices  
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Data collection 
At each selected facility in-charge of OPD, head of clinical teams and head of 
laboratories were interviewed.  In- depth face to face interviews that lasted 17 to 50 minutes 
were conducted using a semi-structured interview guide (appendix III). The interview guide 
was based on knowledge of the TB care cascade and probes for respondent’s own 
experiences or observations at the HF where he or she worked. The guide related to the 
potential problems described in the WHO framework for improving TB case detection and 
treatment (Marais and Raviglione, 2011). 
Interviews were conducted by the principal investigator and a research assistant with 
experience in qualitative research. Respondents were contacted by phone to make an 
appointment for the interview. Before each interview, informed written consent was 
obtained, and no financial or any other form of incentive was provided. Interviews were 
audio-recorded and handwritten field notes were made by interviewer. All audio recordings 
were transcribed by the interviewer and each transcript cross checked with the audio-
recording by the principal investigator for concordance.  
To ensure validity and reliability of study findings, we hired a research assistant who 
had prior experience conducting qualitative interviews. Pilot interviews were conducted at 
two HFs in a neighboring non-study district to assess content, flow and clarity as well as 
acceptability of the study tool. All transcripts were compared with audio-recordings and 
corrections made as appropriate.  
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Data analysis  
This part of the study aimed to understand workers’ perceptions of the relationship 
between service delivery factors and TB treatment delay. Data was entered in ATLAS.ti 
software for coding and analysis by the principal investigator. Data in the ATLAS.ti software 
and interview notes were organized into folders by category of respondent.  Data was 
analyzed using the thematic content analysis in which text data was aggregated and assigned 
a code; similar codes were aggregated into themes. Additional codes and themes emerging 
from the transcripts were added to those already mentioned in table 11. Before coding, each 
respondent’s interview and field notes were reviewed two to three times while highlighting 
major organizing ideas. Code names were mostly based on health sciences and behavioral 
literature. A mix of pre-selected and emergent codes and themes was used. The coding was 
done independently by two people (the principal investigator and someone with experience in 
coding qualitative data) and their findings compared.  
HUMAN SUBJECTS AND SAFETY CONSIDERATIONS 
 Approval for the study protocol was obtained from the Joint Clinical Research 
Center (JC0718) (Appendix 5), Uganda National Council for Science and technology 
[HS205ES] (Appendix 5), and the committee for protection of human subjects at the 
University of Texas Health Science center, Houston (HSC-SPH-18-0264) (Appendix 3). 
Written administrative consent was obtained from the ministry of health prior to data 
collection.  
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RESULTS 
QUANTITATIVE COMPONENT (AIMS 1 & 2) 
Descriptive characteristics 
A total of 1501 adults were tested for TB between January 1st, 2016 and December 31st, 2017 
across the three study districts. Among these were 145 (9.7%) who were diagnosed upon 
referral of their specimens for Gene Xpert testing. As indicated in Figure 5 below only the 
1199(79.9%) patients who were diagnosed and treated at the same site were included in the 
study since only these reached the study end point of treatment initiation.   
 
Figure 5: Study profile  
 
 
 
 
 
 
 
 
 
 
 
TB cases 
N=1501 
Diagnosed at a treatment center 
N=1356 
Treated at diagnosis site 
N=1199 
Diagnosed at off-site lab 
N=145   
Pretreatment 
LTFU*, N=157 
*Loss To Follow Up 
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Structural characteristics associated with treated TB patients  
Sixty-four HFs provide both TB diagnosis and treatment onsite. Kabarole district had 
more HFs (35) providing TB services (three hospitals, two HCIVs and 29 HCIIIs) compared 
to 19 HFs in Kasese (three hospitals, two HCIVs and 14 HCIIIs) and 10 HFs in Kyenjojo 
(one hospital, one HCIVs and eight HCIIIs). Three quarters of HFs with TB services were 
publicly owned HFs compared to the remaining ones that were exclusively nonprofit, 
religious affiliated facilities. In 60 (93.3%) of HFs, the primary TB diagnostic technology 
was microscopy. More than two thirds of HFs small labs had one to two laboratory 
personnel; 50% of the HCIIIs that had only one laboratory worker.  
Table 12: Characteristics of healthcare facilities providing TB services   
Characteristic (N=64) Frequency  Percentage  
Number of facilities in district     
        Kabarole  35 54.69 
        Kasese  19 29.69 
        Kyenjojo  10 15.63 
Types of health facilities    
       HCIII  50 78.13 
       HCIV 7 10.94 
      Hospital 7 10.94 
Health facility ownership    
      Public  48 75.00 
      Private not for profit  16 25.00 
Primary TB Diagnostic technology    
     Microscopy  60 93.75 
     Gene Xpert 4 6.25 
Number of laboratory personnel    
    1-2 46 71.87 
    3-4 9 14.06 
    5+ 9 14.06 
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Table 13 shows HF characteristics associated with treated TB patients. Two fifths 
(41.9%) of the TB cases were from Kabarole district with the rest equally distributed 
between Kasese and Kyenjojo districts.  
Table 13: Structural characteristics associated with treated TB patients 
Characteristic  Frequency (N=1119)  Percentage (%)  
District                                   Kabarole 502 41.9 
        Kasese  348 29.0 
        Kyenjojo  349 29.1 
Health facility level                Hospital 398 33.2 
       HCIII 622 51.9 
       HCIV  179 14.9 
Health facility ownership    
      Public  846 70.6 
      Private not for profit  353 29.4 
Health facility laboratory personnel    
     1-2 469 39.1 
     3-4 271 22.6 
     5+ 459 38.3 
Over two thirds (70.6%) of the patients received TB services in publicly owned HFs. 
All the remaining patients that were treated in  in non-profit religious affiliated healthcare 
facilities.  TB cases at level three health centers (HCIII) were more than those at hospitals 
and level four health centers (HCIV) combined. The total TB case load at HCIIIs was 1.6 
times those at hospitals and 3.5 times those at HCIVs. However, hospitals had a median of 64 
TB cases (IQR, 49-71) compared to 17 (IQR, 12-65) at HCIVs and 8.5 (IQR, 5-22) at HCIIIs 
reflecting a relatively low number of cases in hospitals and HCIVs compared to HCIIIs.   
Close to two fifths of TB cases were diagnosed at HFs with one to two laboratory personnel 
including 207(17.3%) patients diagnosed among HFs (HCIIIs and HCIVs) with only one 
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laboratory staff. Nearly two fifths of the patients were diagnosed at a HF with five or more 
laboratory personnel.  
Personal characteristics of TB patients treated at diagnosis sites  
There were 111(16.9%) less TB patients in 2017 compared to the 655 that were 
treated in 2016. The mean patient age was 36.9 (SD, 14.3) years with three in four patients 
(75%) aged less than 45 years. Males represent 2.4 times (70.2%) as many cases of TB 
compared to females (29.8%). Less than 5% of TB patients had previously been treated for 
the disease. Close to one third (31.2 %) of the patients were HIV positive469 (39.1%). 
Characteristics of the treated TB patients are summarized in table 14. 
Table 14: Demographic characteristics of treated TB patients  
Characteristic  Frequency (N=1119)  Percentage (%)  
Age in years (mean, SD )*              36.9 14.3 
Gender                                         Male 843 70.2 
           Female  357 29.8 
HIV status                              Negative 792 66.1 
          Positive  374 31.2 
          Unknown  33 2.7 
Previously treated for TB              No 1166 97.3 
         Yes  33 2.7 
Year of diagnosis                         2016 655 54.6 
         2017 544 45.4 
*Described in terms of median with corresponding standard deviation 
Care delivery characteristics of treated TB patients  
Disease diagnosis was based on a single test per specimen submitted. Approximately 
six in ten patients (59.3%) were tested for TB two or three times during the care episode. Of 
these 711 patients that had a repeat test, 655 (92.1%) had a positive index test, demonstrating 
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a high rate of retesting even when the first specimen is positive. Disease diagnosis centered 
on microscopy technology. Eighty-one percent of patients were diagnosis based solely on 
microscopy while 168(14%) were diagnosed using the Xpert test only. Compared to use of 
the Xpert test, two thirds (65.6%) of single-test based diagnoses and 92.5% of retests were 
solely microscopy based. Microscopy was the preliminary test for in all patients who had an 
Xpert test as their repeat test.  
As shown in table 15 below, only 20 percent of patients visited the laboratory for 
testing on a weekend; most patients were tested during the week.  
Table 15: Care delivery characteristics of treated TB patients  
 
  
 
 
 
 
 
 
 
 
Characteristic  Number  Percentage 
Technology used for diagnosis    
     Microscopy  978 81.6 
Gene Xpert 168 14.0 
     Both tests 53 4.4 
Samples tested    
      1 488 40.7 
      2 684 57.0 
      3 27 2.3 
Laboratory test sequence    
      Single test  488 40.7 
      Repeat after negative result 56 4.8 
      Repeat after positive result  655 54.6 
Weekend lab test   
    Yes  242 20.2 
    No  957 79.8 
55 
 
Duration of Tuberculosis care processes  
The median TB treatment time was one day (IQR 1, 3). Slightly over half (52.3%) of 
the patients received TB test results and started treatment on the same day they first visited a 
facility for testing. Further, 75% of patients started treatment with three days of their initial 
visit for a TB test.   
The time intervals of laboratory turnaround time (TAT) and treatment initiation time 
(TxIT) are summarized in table 16.  
Table 16: Tuberculosis care process durations in days  
Process duration (days)     Median* (Q1,Q3)  Minimum Maximum 
Laboratory TAT 1(1,2) 1 108 
Treatment initiation time 
 
1 (1,1) 1 88 
Total treatment time 
      
1 (1,3) 1 108 
*1 day =same day event  
The median laboratory TAT was 1 day (IQR 1, 2), which was like the treatment 
initiation time. Two thirds of the patients received TB test results on the same day they 
submitted a specimen for testing.   
The proportion of TB patients starting treating treatment rapidly rose to 
approximately 90% within the first six days and tapered off. By day fifteen, 95.8% of the TB 
patients had started treatment, up from 71.4% by day three. There was no statistically 
significant difference in the patient, health facility and care delivery characteristics between 
these patients starting treatment within 14 days and those whose treatment was extremely 
56 
 
delayed.  The rest of the study findings are based on these 1142 (95.2%) TB patients that 
were initiated on treatment within 14 days of first visiting the laboratory for a test. Because 
this small number of outliers would greatly affect regression analysis of typical treatment-
initiation times, they have been excluded from outcomes analyses. To understand the small 
portion with anomalous, egregious delays, a separate examination of those should be 
conducted. 
Association of service delivery factors with duration of TB care processes 
We considered the relationship of service-related factors with laboratory TAT and 
then with treatment initiation time (TxIT).  Process times (TAT and TxIT) were minimally 
correlated (r = 0.06, p= 0.029) but each had a strongly positive correlation with total time (r 
= 0.85, p<0.001 for TAT, and r= 0.58, p<0.001 for TxIT). Among care delivery 
characteristics, number of TB specimens tested had a strong positive correlation with 
sequencing of tests (r= 0.87, p<0.001) indicating that each extra specimen collected meant a 
repeat test had been ordered.   
Association of service delivery factors with laboratory turnaround time   
 Table 14 describes multivariable analysis for TAT. The following patient and 
structural factors with p-value > 0.25 at univariate analysis were not selected for 
multivariable regression: age of the patient (p=0.661), gender (p= 0.957), previous history of 
TB treatment (p= 0.873), year of diagnosis (p=0.627) and HIV status (p=0.61).  
Factors that independently predicted laboratory TAT were submitting a TB specimen 
to the laboratory during a weekend and having a repeat TB test (table 14). Submitting a 
57 
 
specimen over the weekend increased laboratory TAT by 0.37 days compared to specimens 
submitted during the week, (ẞ=0.37, 95%CI 0.11, 0.60). Patients who had a repeat TB test 
after initially testing negative had 1.17 day longer TAT than those who had a single test 
(ẞ=1.17, 95%CI 0.64, 1.69). However, a repeat test after an initial positive test did not 
change laboratory TAT (ẞ=0.22, 95%CI -0.02, 0.46) pointing to urgency in reporting each 
individual positive result. Laboratory turnaround did not differ by type of TB test conducted 
(ẞ=0.29, 95%CI -0.08, 0.65 for Xpert test compared microscopy) and whether a patient was 
tested at a health center compared to a hospital (ẞ=0.10, 95%CI -0.16, 0.35 for HCIII and 
ẞ=0.26, 95%CI -0.08, 0.59 for HCIV). 
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Table 17: Association of service delivery factors with durations of TB care process  
Characteristic  TAT     (N=1336) Treatment initiation time  (N=1336) 
Univariate analysis Multivariable analysis Univariate 
analysis 
Multivariable 
analysis 
ẞ (95% CI) ẞ (95% CI) ẞ (95% CI) ẞ (95% CI) 
Health facility level              
HCIII 0.04(-0.18,0.26) -0.06(-0.62,0.49) 0.04(-0.14 ,0.22) 0.26(-0.19,0.70) 
     HCIV  0.81(-0.13,0.49) 0.13(-0.30,0.56) -0.11(-0.36,0.14) -0.01(-0.35,0.34) 
Health facility ownership      
Private  -0.12(-0.34,0.10) -0.22(-0.49,0.05) -0.07(-0.25,0.11) -0.17(-0.39,0.05) 
Laboratory personnel            
3-4 0.19(-0.08,0.46) 0.10(-0.23,0.44) -0.29(-0.50,-0.08) -0.07(-0.34,0.21) 
     5+ 0.02(-0.21,0.24) -0.09(-0.66,0.48) -0.07(-0.25,0.11) 0.26(-0.20,0.73) 
Weekend lab visit     
Yes  0.35(0.10,0.59)   0.37(0.11,0.62)* 
 
-0.02(-0.23,0.18) 
Technology used     
Gene Xpert 0.05(-0.24, 0.34) 0.30(-0.10,0.69)  0.39(0.07 0.71)* 
     Microscopy and Xpert -0.04(-0.54,0.49) -0.36(-0.89,0.17)  0.01(-0.42,0.43) 
Lab test sequence         
 Repeat after negative result 1.09(0.59,1.59) 1.23(0.70,1.75)* 0.48(0.08,0.89) 0.51(0.08,0.93)* 
Repeat after positive result 0.12(-0.09,0.32) 0.21(-0.04,0.45) 0.14(-0.02,0.31) 0.26(0.06,0.45)* 
District     
                     Kasese  0.26(-0.03,0.54) -0.14(-0.34,0.05) -0.16(-0.39,0.07) 
Kyenjojo   -0.08(-0.38,0.21) -0.28(-0.48,-0.09) -0.42(-0.66,-0.18)* 
*P-value<0.05 
 
Association of service delivery factors with treatment initiation time  
Table 14 also describes results of multivariable analysis for treatment initiation time. 
The TxIT for patients in Kyenjojo district was 0.42 days less compared to those in Kabarole 
district (ẞ = -0.42, 95%CI -0.66,-0.18). Receiving treatment at a HCIV was associated with 
0.3 day shorter initiation time than at a hospital (ẞ = -0.29, 95%CI -0.56,-0.02) but there was 
no difference when HCIIIs were compared to hospitals (ẞ = -0.12, 95%CI -0.32, 0.08). 
Having had a repeat TB test significantly increased TxIT irrespective of the initial test result 
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(ẞ = 0.51, 95%CI 0.08, 0.93) for an initial negative result and (ẞ = 0.26, 95%CI 0.06, 0.45) 
for an initial positive result).  
Association of service delivery factors with treatment delay 
The rate of TB treatment delay was 25.0% (95% CI 22.6%, 27.7%). For the 
multivariate analysis, the following patient and HF structural characteristics with p-value 
>0.25 at univariate analysis were excluded: year of diagnosis (p=0.975), previous history of 
TB treatment (p=0.585) and HF ownership (p=0.725).   
As summarized in table 15 below, the odds of delay were 1.79 times when Xpert test 
was used for diagnosis compared to microscopy (adjusted OR [aOR] 1.79, 95%CI 1.04, 
3.10). Compared to having a single test, having a repeat TB test significantly increased odds 
of delay; 3.5 times if index test was negative (aOR 3.49, 95%CI 1.81, 6.75) and 1.8 times if 
index test is positive (aOR 1.81 95%CI 1.27, 2.60).  The odds of treatment delay were two 
times more (aOR 2.06, 95%CI 1.49, 2.84) when a patient presented on a weekend compared 
to a week day.  
Receiving TB services at a health center (aOR 1.58, 95%CI 0.73, 3.42 for HCIII; 
aOR 1.28, 95%CI 0.73, 2.24 for HCIV) compared to a hospital was not associated with TB 
treatment delay. No patient characteristics had a statistically significant association with TB 
treatment delay. 
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Table 18: Association of service delivery factors with TB treatment delay  
Characteristic 
Delayed, 
n (%) 
Crude OR 
(95% CI) 
Adjusted OR 
(95%CI) 
District     
Kabarole  120(25.1) 1.00 1.00 
Kasese  100(30.3) 1.32(0.95,1.78) 1.34(0.91,1.97) 
Kyenjojo  66(19.8) 0.74(0.53,1.04) 0.72(0.48,1.08) 
Health facility level              
Hospital 105(27.1) 1.00 1.00 
       HCIII  140(24.0) 0.85(0.63,1.14) 1.58(0.73,3.42) 
       HCIV 41(24.0) 0.85(0.56,1.29) 1.28(0.73,2.24) 
Lab Personnel                             
1-2  105(23.8) 1.00 1.00 
3-4 56(22.1) 0.91(0.63,1.31) 0.98(0.62,1.56) 
5+ 165(28.0) 1.24(0.92,1.68) 1.75(0.79,3.89) 
Weekend lab visit                      
No 201(22.1) 1.00 `1.00 
       Yes 85(36.4) 2.02(1.48,2.76) 2.06(1.49,2.84)*      
Technology used         
Microscopy  228(24.4) 1.00 1.00 
      Gene Xpert 26(28.2) 1.22(0.84,1.77) 1.79(1.04,3.10)*     
      Both  12(26.7) 1.13(0.57,2.22) 0.71(0.35, 1.47) 
Test sequence      
Single test  103(22.0) 1.00 1.00 
      Repeat after negative result 22(44.0) 2.79(1.53,5.09) 3.49(1.81, 6.75)* 
      Repeat after positive result  161(25.8) 1.24(0.93,1.64) 1.81(1.27, 2.60)* 
Age      
                                       years  286(25.0) 1.00(0.99,1.01) 1.00(0.99, 1.01) 
Gender    
                                Male  194(24.3) 1.00 1.00 
           Female  92(26.7) 1.14(0.85,1.52) 1.08(0.78,1.46) 
HIV status                          
Negative  176(23.3) 1.00 1.00 
          Positive  98(27.8) 1.27(0.95,1.69) 1.35(0.99,1.84) 
          Unknown  12(36.4) 1.88(0.91,3.90) 1.75(0.82,3.78) 
*P-value<0.05 
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QUALITATIVE COMPONENT (AIM 3) 
Sample and field work description 
A total of 27 face-to-face interviews were conducted with three representatives from 
each of 9 (three hospitals, three HCIVs and three HCIIIs). The mean age of respondents was 
32.4 years (SD 6.9). There were 8 female and 19 male respondents; all six females serve as 
heads of OPD services and three females were clinical team leaders; all heads of laboratory 
services were males. Respondents for head of OPD services comprised of five nursing 
officers (Hospital =2 and HCIV = 3), two clinical officers (one at a hospital and another at a 
HCIII) and two enrolled nurses (both at HCIIIs). Among heads of laboratory teams were 
three laboratory assistants (Hospital =1, HCIV = 1 and HCIII=1), five technicians (Hospital 
=2, HCIV = 1 and HCIII=2) and one technologist (at a HCIV). All heads of clinical teams 
were clinical officers.  
All interviews were conducted at the health facilities during working hours.  With 
exception of one laboratory assistant representing the laboratory services head, and two 
enrolled nurses representing the head of OPD services, all respondents were appointed heads 
of services. Except for two respondents (both heads of lab at HCIVs) who had to be re-
interviewed due to interruptions, all the interviews were completed in one sitting. The 
interviews lasted on average 30 minutes. During the interview it was observed that most 
respondents answered each question individually instead of broadly discussing the subject. In 
this case, interviews were conducted in a question and answer fashion often with prompting 
to encourage them to continue talking.  Because of patient confidentiality issues it was not 
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possible to observe respondents in the TB care process. Respondents generally were 
unwilling to describe what they did as individuals. Even where a respondent identified a 
problem in his/her unit, this was attributed to workmates. However, each respondent was able 
to confidently describe patient flow even at service points where she/he did not work.   
Coding and themes development  
Initial reading of transcripts was done within two days of conducting each interview, 
but coding was done after all interviews were completed. Because each respondent discussed 
the whole TB patient care flow map, there were little differences among the respondent 
categories.  
Focus at theme development was on descriptions and explanation of practices that a 
respondent felt resulted into delays in the TB care process. Most of the preselected codes 
groups were identified during the coding process but were interrelated in a much different 
way from groups and themes from existing literature. Workplace safety was the only theme 
that emerged as having a direct relationship with TB treatment delays. The remaining 
themes, though widely cited in literature on implementation of infection control measures, 
were not directly related to patient care delays. All respondents reported good comprehension 
of recommended practices so lack of knowledge was not a cause for delays.  
Besides work environment safety (renamed as concerns about spread of TB amongst 
healthcare workers), there were five emergent themes. These were perception of delays 
among healthcare workers, attitude towards attending to TB patients, care decision making 
approach, schedule of TB care tasks and their completion, stock out of TB drugs and 
supplies. Each theme is addressed in detail below:  
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Perception of delays among healthcare workers  
Across the three respondent categories, quickly attending to presumptive TB cases 
was primarily to prevent disease transmission. Regarding transmission, workers explained 
that quickly initiating anti-TB drugs reduced chances of workers or other patients contracting 
TB. A laboratory technologist viewed this as an infection control measure with benefits to 
healthcare workers and the wider community observing that “we will have put there (sic) 
control measures for the staff not to be infected with TB. And also we will have safeguarded 
the community…we will have really improved [health] in the community that we are serving 
and it will also help us to be healthy” (R5-02)   One respondent also observed that timely 
response improved patient satisfaction with services, noting thus: “You know when you 
delay a patient, the patient also loses morale, and next time the person gets sick, [he or she] 
may fail to come to the facility [where he has previously experienced delays]”(R4-01).   
At all facilities, respondents felt patients with TB ought to be diagnosed and treated 
within 20 minutes to a few hours of presenting for consultation. Most respondents agreed 
they could attend to TB patients in a much shorter time than they were currently. 
Interviewees suggested that a threshold of within a day but felt that it was not generally 
achievable, especially when there was a heavy workload or a patient presented towards the 
end of business hours. One respondent who proposed more than a day as a cut off threshold 
for defining delay observed that “A day or two [is a good cut off]….because ….sometimes 
you find the lab very busy [with] many TB sputum tests [and] delays to give them the results 
that day ….sometimes they are promised (sic) to come the next day” (R5-01). Another one 
argued that:  
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At least if it is very long [it shouldn’t last more than] one day. But it depends. If a patient 
came like around evening hours, he may be told to come back tomorrow. Now let’s say like 
here we work up to 5. If a patient is screened like at 4 and is sent to the lab and by the time 
the lab person does the whole process, to stain and get the results, it might be 5. And this 
patient is told to bring another sputum in the container the next day. So this one may be call 
for coming back tomorrow (R7-01) 
Comparing TB care points, all three categories of respondents agreed that the most 
time was spent in the laboratory and therefore that is where most delays occurred.  A clinical 
care team head who felt that longer periods spent in the lab had to be considered while 
defining upper limits of duration of a TB care episode observed that:  
“… Maximum time [to get tested and started on TB treatment] should be five to six hours. 
Yeah because I know...... But because I know the only delay is in the lab. The rest are okay. 
What I know in the lab they wait for two, three hours ….but then there is some information 
am not well acquainted with how much time it takes to diagnose and to come out with clear 
results in the lab” (R1-01) 
A laboratory technician concurred but argued that specimens are not brought on time. He 
argued that “… when the [samples] come in the lab as soon as possible, of course the 
treatment is also done very early. But when the [samples] delay, the treatment also does 
delay….delay in treatment depends on the release of the results. ….we don’t just tell them 
that go to the clinicians, we just escort that patient direct to the clinician” (R6-01). A clinical 
officer heading a clinical team at a busy hospital even suggested that with the prevailing 
workload it was better to have a standalone TB laboratory to reduce delays in testing and 
reporting TB tests.  
What I think, I can now look at the lab side first, if there could be a separate lab that is to 
handle that [big number of TB tests] so  as to avoid the overload. The OPD patients, ANC, 
may be samples from the ward, so that overwhelming number, if there could be a separate 
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lab, then it could be of function. …the greatest time is actually taken in the lab while 
processing sputum sample. (R6-03)  
 Asked what caused treatment delays, most respondents first mentioned external 
factors, like low stock levels of TB drugs and diagnostic supplies.  One respondent was 
emphatic saying that only stock outs of drugs and supplies caused delays stating that “I don’t 
think there is [any other cause of delays] apart from drug stock outs …apart from those items 
like lack of may be sputum mugs. You find that they are out of stock, ahh slides and stains. 
Those are the only things that can cause delay at this healthcare facility” (R8-03). A 
laboratory technologist at a HCIV also noted stock out of supplies as a top cause of delays 
saying “The first issue [causing delays in treating TB] will be the supplies. We don’t have 
supplies like sputum mugs. Like for children you have to do gastric lavage” (R5-02). 
 The understanding was that health facilities could aim for shorter time windows 
within which presumptive TB cases could be identified and treated. Improving laboratory 
turnaround times and having sufficient levels of supplies were key to reducing time windows.   
Concern about contracting TB 
Presumptive TB cases were seen by staff as different from other patients solely on 
account of having an infectious disease, which might impact staff and other patients’ health.  
A clinical officer observed that “They are like any other patient [in all other aspects] but 
because they have the infectious disease, they can transmit the bacteria to another person. So 
you cannot keep them with other patients” (R9-01).  A comprehensive nurse heading OPD 
services at a HCIII explained that:  
They are like the same patients but them, I handle them in a special way because they, they’re 
infectious patients. I don’t see them like malaria patients because they are infectious. The 
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way in which we handle them? First of all, these patients are contagious, we triage them. So 
when they come and we know that these are our clients, we give them a special place, a 
special place where to sit. They don’t sit with other clients (R8-01) 
Another explained the great length they went to ensure that presumptive TB patients 
understood why they were being isolated from the rest of the patients saying “Yes we treat 
them differently from other patients…. but after getting them, after screening them and 
confirming them. Of course [as we isolate them] we health educate and we try to explain, 
how infectious TB is and how it is spread” (R1-01). 
Respondents expressed their fear of contracting TB from patients in different ways. A 
clinical officer heading OPD services narrated that “But I do fear, to get TB each time, I have 
this thing in me each time I look at a TB client, I also start coughing” (R6-02).  A laboratory 
technician appeared to worry more about his workmates saying “Actually we are worried that 
our staff might contract TB anytime because of those infection control measures not being in 
place” (R4-02). A female clinical team head was more worried about acquiring TB and 
transmitting it to children in her household saying “Some [of us]  fear … like I have a child 
at home so if you give it to me I will take it to my baby at home” (R9-01). Having measures 
to protect staff at the health facility helped to lessen fears. One respondent who felt they had 
adequate measures and this had lessened his fears, “I don't have fears because in most cases 
we are given face masks. We are also taught about other preventions, like opening windows 
and doors; the coughers to always cough in their hands or handkerchiefs to stop the spread of 
the bacteria. So I don't see how I can fear because the simple methods to use are there” (R4-
03) 
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Even those who strongly felt they were at risk of acquiring TB, it did not affect their 
personal attitude towards attending to TB patients. A head of OPD services who felt 
frustrated that personnel did not see themselves as being at most risk reported he had 
embarked on in-house sensitization about risk of TB. She observed that by appreciating their 
own risk, less staff shunned attending to TB patients:  
 And some staff, after knowing that they  are at risk and we have a higher risk, people, some 
people appreciated to work on them so fast so that they can go….To take the care, to take that 
caution to make sure that we are not infected especially when I wanted to show them the 
register that even wanted to capture the number of health workers being affected by TB…..So 
people started fearing TB and so, one would manage in order to protect himself or herself and 
even protect the patient…..Yes. But at first it was like hmm may be she is being paid for it. 
You can go and see her, she is down, you go with the register…..those days they were not 
assisting (R5-01) 
Healthcare workers working with TB patients never felt discriminated by the rest of HF 
staff suggesting risk of contracting disease from them was perceived to be low. Further, it 
was perceived that all staff had some level of exposure to TB during their duty and therefore 
no one individual could be singled out as being more likely to spread disease than others. 
One outpatient clinician team lead observed that because everybody in her unit attended to 
TB patients, they shared risk and therefore nobody could be seen as being any different. She 
reasoned that “[here] Hhmm there is no that discrimination because for example, you may 
find that everybody in OPD has worked on the patient not only me. Because somebody 
registered another one did vitals, then me I touched, the patient continues, so you may not 
pinpoint [who is responsible for TB services]” (R9-01). Even when called a nickname with a 
suffix of TB, this in anyway did not make one TB service provider feel she was being 
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discriminated by other staffs. In stating that this did not affect her commitment to work, she 
observed that:   
 We even have nicknames, they even call you [her first name] TB…..they say it in good faith, 
they give you a nick name…. I don’t have any problem with it. They don’t have any problem 
they don’t even say anything [bad about your work], they just know you as Rosette who 
works on TB clients or Florence who works on TB clients that’s all or Violet who makes 
reports for TB drugs just (R9-01). 
In expressing fear of getting infected, respondents were worried about themselves as well as 
family members. Fear was heightened by lack of personal protection measures. However, 
this did not affect their attitudes towards attending to TB patients; nor did it translate to their 
being stigmatized by others for providing TB services. It was believed that understanding 
one’s risk could potentially change attitudes towards attending to TB patients.  
Determinants of attitude and willingness to participate in providing TB care  
Even as they attended to TB related tasks, most respondents expressed preference for 
tasks that did not involve TB patients. A laboratory services head shared his experience 
working in a well-staffed hospital noting that “The experience is that as in lab (eeh) people, 
most of the people don’t like (eeh) working on TB clients. Though it is in most 
cases…though it is in most cases a requirement but people don’t do it with a ‘good heart’” 
(R9-02). Attitude to TB related tasks within anyone HF varied with some staffs giving 
excuses to avoid attending to presumptive TB patients while others willingly participated in 
TB care. TB care was often left or referred to the latter group and patients had to wait if they 
were busy with other tasks or were absent. It was felt that staff were simply giving excuses 
when they claimed to lack knowledge and skills necessary to participate in TB care. A 
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nursing officer at a HCIV who attended to TB patients despite not having had training 
remarked that “I think they may think we are the only health workers who are experienced 
.But I think they have no interest, because here the health workers who ever gone for TB 
workshops, they are two. I personally am not there, but I think I am going an extra mile to 
ask them how we are to handle these patients” (R8-01). Another respondent was more 
concerned about individuals who are trained but still had a negative attitude reasoning that:  
[Negative attitude] has caused delays and actually not only delays but even we have lost 
clients, because not every staff… is actually a well-wisher for diagnosing or assessing one 
with TB. So, even if you give this person knowledge ….you will never induce this person to 
do something that his mind or her mind has not actually welcomed. So there is a knowledge 
gap, but which is attitudinal coated also.(R4-02) 
Negative attitude to TB care was attributed to several factors. A nursing officer observed 
while some had fear of contracting TB, others were reluctant to take on the time consuming 
tasks in dispensing TB medicines. She observed that “That negative attitude….we have 
different levels of training. One thinks if I interface with this patient, he is going to give me 
TB. Another one may say now, I have to go to the registers, now I have to fill the cards, now 
I have to fill the drugs ah…and even [I don’t have] the confidence” (R4-01). One respondent 
reasoned that dispensing was shunned because of the paperwork one was required to fill 
before issuing drugs noting that “Most people think (sic) this thing of recording… they are 
not interested” (R5-01). In other instances questions about selective facilitation often 
contributed to negative attitude. One respondent had noticed other staff thought she was 
being facilitated saying “Hmm yeah partly because someone will feel like you are given 
airtime, you are given an allowance so this is your job not mine” (R9-01).  
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But because attitude among HF staffs varied, there was always at least one individual willing 
to see TB patients if designated personnel were absent and could not easily be reached. A 
clinical team head reasoned that “You see we have different attitudes yeah, some others may 
even say no for me…those clients are for so and so, he is the one who treats those clients 
…..Some others say no, let’s treat this patient because we may acquire diseases, so we have 
different attitudes” (R8-03). 
It was also observed that several circumstances resulted into personnel changing their attitude 
and attending to TB patients. A nursing officer had noticed often staff changed attitude after 
observing others attending to patients noting that “But the moment they see us working on 
the patients, they also they improve but gradually. The improvement would be gradual 
slowly by slowly, even for the other people who had very negative attitude, after the training 
they can work with me” (R5-01). A laboratory assistant noted that improving perception of 
one’s risk also changed attitude emphasizing that:  
[Awareness] should be created on the burden of TB. So they [healthcare workers] 
should appreciate how tough or how bad TB is. And they should know the route 
despite you dodge it from the facility but the person you dodged at the facility but you 
meet him in the vehicle or along the bar or whatever you might think T B is just 
coming to the facility but at any later time you will get it anywhere from the person 
you actually distanced yourself from (R4-02). 
In summary, most healthcare workers preferred to attend to non-TB related tasks but were 
compelled by the duty assignments. A number of factors that included fear of acquiring TB, 
lack of experience, complexity of tasks involved in TB care and suspicions of selective 
financial motivation shaped attitudes towards attending to TB patients.  Lack of knowledge 
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and skills to attend to TB patients was a commonly used excuse to avoid attending to TB 
patients.  
Scheduling and completion of TB care related tasks 
There were standardized protocols for attending to presumptive TB cases that 
emphasized prioritization of their care at all service points within a health facility. This was 
done alongside attending to general patients. Some respondents said they suspended ongoing 
tasks whenever they received a presumptive or confirmed TB case to give them priority. A 
female clinical officer heading OPD services observed that to her TB care was a priority 
ranking next to life threatening illnesses. Community volunteers and some other staff at 
triage reminded responsible personnel to attend to these patients in isolation corners so they 
could quickly leave HF premises.  At work stations, presumptive TB cases were checked for 
among waiting patients and attended to first. The following expressions exemplify 
prioritization of TB care over other tasks at work stations. A clinical officer who doubled as 
head of clinical team stressed that “Well, the first thing as I told you, when you ....you can 
get a person with TB [symptoms], we give them a chance and ….send them to the lab. Then 
in the lab, at least they are given a chance faster to make sure they work upon them” (R5-03). 
Even in the laboratory a respondent who routinely checked for TB patients among waiting 
patients reported that “if somebody is sent in the lab for TB, actually I give them the first 
priority to work on them. If I leave them there, they might spread to other clients ….once 
they sit there, as I am passing through I ask them, I check in their books” (R7-02). There was 
more urgency once a patient was confirmed to have TB than while still undergoing tests. A 
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laboratory assistant at a HCIV emphasized that, “When we produce results ……supposing 
the result on the spot came to be having or containing mycobacterium bacilli, we start that 
person, rather there and then on anti-TB drugs” (R4-02). A clinical officer described how 
they often escorted newly diagnosed TB patients saying that:  
…. remember on the dispensing window, there are many other patients who may not have TB 
so we normally prefer after prescribing, we give it [prescription form] to the VHT….. Who 
takes the patient to the dispensing nurse and ….the dispensing nurse ….will call the patient 
and give treatment immediately before others. (R7-03) 
But checking for presumptive TB cases among patients in the waiting area was not done all 
the time. One laboratory technician stated that in his HF, triage was done only in the morning 
hours; and on some days not done at all. Patients with TB symptoms who presented when 
checking was not being done were attended to like any other patient on a first come, first 
served basis. A laboratory technician expressing frustration with failure to segregate between 
patients being sent for TB tests and others observed that, “triage is done first thing in the 
morning. Normally, when they do the triaging in the morning, the results normally takes 20 
to 30 minutes. ….. Those who come after the triage process, because triaging is done first 
thing in the morning we [see them]… on first come first serve [basis]” (R1-02). Another 
laboratory technician who was concerned that TB patients mixed with other patients in the 
waiting area reported that:  
Yeah, actually, the biggest huddle in contribution to the delays of these patients is 
lack of a clear triage system in the facility. So when they [all patients] come here, it is 
just a mixture and there is no one to sort them out like this one has this problem, this 
one has this problem, the can be categorized and worked on according to their needs 
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because you know that someone who is presumed to have TB is dangerous to the 
community. (R5-02) 
Even if presumptive TB cases were identified early enough, there were often 
competing tasks, in which case one either both the TB patient and other task simultaneously 
or first completed an ongoing task before attending to a TB patient, which caused delays. A 
head of OPD services at a hospital who often had competing priorities remarked that “you 
see, there are some cases that you can’t just escape for one patient someone is dying there 
and your like let me first work on this one ….[presumptive TB case]” (R6-01). Another one 
urged patience with the laboratory where they had one laboratory personnel observing that 
“….. Sometimes we send some clients to be screened in the lab and we find the lab also 
having some test it’s carrying out or as we continue also with the programs of the health 
center. So, we also give some time to do those things” (R8-01). One respondent observed that 
on HIV clinic or immunization outreach days, personnel took on extra responsibility, which 
conflicted with attending to TB patients in the OPD. This prolonged wait times for TB 
patients at triage, testing and even starting treatment:   
…..on ART [Anti-Retroviral Therapy] clinic day, there are many clients. Somebody may be 
screened for TB and is being sent in the lab, we work on that client but taking back the results 
,you find [prescriber] is not there he has gone down to attend [to] the ART clinic patients. So 
I have to go down and call for [him or her] in case if the patient is having TB. (R7-02) 
One respondent reported that TB patients were attended on a first come first serve basis in 
the interest of being fair to patients who had waited for long. In such a case presumptive TB 
cases would sent to the isolation corner and attended to after the queue had been substantially 
reduced. This respondent who felt he had a moral obligation not to discourage patients with 
non-TB related illness noted thus:  
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 … You tell them [non TB patients] that your tests are going to be out in 30 minutes, and a 
TB client comes, if you are to first go and work on the TB client, then it means you are going 
to delay the other one you told that the tests will be out in 30 minutes. It is always 
challenging in that way but now if these people come later and find us in the middle of 
digging, they are the ones who are going to wait. They will be affected, somehow, 
somewhere. (R4-02) 
Furthermore, some healthcare facilities had set specific times during the off-peak hours when 
TB tests were conducted. In this case patients had to wait until it was time to run TB tests and 
report results or were given an appointment to return for the results. Tests were often done in 
late afternoons or evenings when the clinic was less busy. A clinical officer who expressed 
frustration with turnaround times of TB results observed a much shorter time was spent 
deciding whether to treat on clinical grounds or not than was spent conducting a lab test.   A 
laboratory technician admitted that unless urgency of the test was expressed, both samples 
were collected over two successive days and tested at once. He reported that:  
It [getting results on the same day a test is requested] always happens may be if this client is 
coming from OPD and is an out-patient and is going back… That’s when you find that a test is 
requested and it is done there and then.... [When] a doctor wishes to see the results of the spot 
sample. But for these other ones who are on ward, may be ART, clients hurry to collect the 
samples but we haven’t been in a hurry to examine the samples….Because we give out results 
after examining two sputum samples. (R9-02) 
Several reasons were given for running tests in batches collecting all the patient’s TB 
specimens first and/ or having each day’s tests done at once. A head of OPD services 
sympathized with the laboratory staff noting the heavy workload involved in TB testing 
compared to other tests:  
In case if you are busy with the facility work. Now you may find the lab man is having a lot of 
people of TB, he is having people of HCT, he having and other tests like H-pylori, there are what. 
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Then you find he has to first stain, and then leave them to dry, and then he first works on these 
patients then after he will carry out the testing in the afternoon when he is off duty. (R4-02) 
Respondents involved in laboratory services felt testing samples in batches reduced the 
period when staff were exposed to possible infection as well as reducing cleanup time needed 
to transition between TB and other tests.  
That’s how I found it hear but ideally I think we are trying to minimize exposure [to 
infection]. Exposure…working on one sample and after 30 minutes another client brings in 
another sample. Trying to minimize exposure so they decided to work to collect and to gather 
them and to process them at once (R9-02). 
…we collect all the sputum and work on them at once….. it doesn’t matter whether you are 
the first or the second or what….because this procedure for ZN [TB testing], its nature if you 
separate these patients so much, you waste reagents, then two, you may not …ah you may 
make mistakes here and there…..we give them at least ten minutes apart .We first clean off 
the other stuff (sic), then you begin again. So you would rather prepare the samples at 
once…it saves you time. If we had someone responsible for doing that procedure [TB testing] 
alone … just waiting for TB specimens. (R5-02). 
Therefore, just as much as attempts were made to check for presumptive TB cases and give 
them priority, this was not done regularly or at well in some HFs. In HFs that were 
understaffed, there were often competing priorities, which resulted into patients waiting for 
long hours before they were attended to. To compound the above problems with scheduling 
of TB tasks, laboratories had institutionalized work routines that involved attending to TB 
patients at specific hours in batches.  
Care decision making  
Treatment protocols are used routinely to identify presumptive TB cases, conduct test 
and prescribe treatment. Even after presumptive TB cases had been identified using a 
screening protocol, a second opinion was often sought from a clinician before ordering the 
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TB test. A 29 year male clinical officer leading a clinical team at a HCIII reported what was 
routinely done at his HF noting that “So we screen them and if we think others they don’t 
qualify hmm other it can be minor RTI, hmm, we send them to the lab”(R7-03). An enrolled 
nurse acting as head of OPD services at a hospital was more explicit:   
We receive these patients at OPD, with mostly complaints related to cough and we normally 
ask questions [as] per WHO card [screening guide], to find out the real case of TB, in case it 
is there. After finding out those signs and symptoms of fevers and uncontrolled weight loss; 
after all that, we take these patients mostly to the clinician, and the clinician does further 
examination. And then after that if the patient requires x-ray we do chest x-rays. If the patient 
requires sputum analysis or requires doing any other investigations, we send them to the lab. 
(R2-01) 
Besides seeking a second opinion, some facilities have HFs designated personnel to 
conduct specific TB care procedures. Such procedures were left until the designated person 
was available or deferred if she/he was absent. One laboratory technician reported often the 
staff had to discard patient samples because the clinician meant to refer a case was not 
available, stating that:  
You find a client [who] has been sent to the lab…. needs a gene expert ….. this specimen is 
supposed to be referred but you need a filled referral form [issued] by a clinician or a doctor. 
So the delay happens when this client…when the clinician, the time to fill this referral form 
the time he is communicated to, you find this clinician has delayed to fill this form and 
eventually even in the specimen ends up misplaced from the lab because of lack of this 
referral form… it would be better if these referral forms were designed to be filled from the 
lab (R9-01) 
At the level of starting treatment, patients had to wait for a designated staff (TB focal 
person) to dispense the medicine. A TB focal person at a HF boasted that, “A few people are 
dealing on these anti-T.Bs, because people who initiate people on anti-TBs… I think it could 
be me, the in-charge and even maybe the lab man. I think no one [else] can do this” (R8-01). 
77 
 
Another one however observed that often the focal person was busy attending to other tasks 
and patients had to wait for long hours 
Then when the results are got, and we realize that this patient is a case of TB…….we call in 
the TB focal person to come and witness (sic) the case. So this case is always sent to the TB 
focal person for treatment and other advice that is related to TB treatment and other 
procedures…..she might be busy and you need to take this patient to the focal person for 
treatment and management. So it might take some time. (R2-01) 
Regarding care decision making, patients delayed either waiting for designated personnel to 
whom TB care tasks had been left or waiting for a second opinion before sanctioning 
stipulated TB care procedures.  
Availability of necessary drugs and other supplies  
Respondents expressed frustration when they diagnosed TB patients only to find out 
there were no drugs for their treatment. Available quantities were small and often got used up 
with a single TB patient. It was noted there were weaknesses in the supply chain with 
supplies being inadequate or lacking completely. One respondent observed that the available 
supplies are usually adequate for one to two patients, beyond which the HF immediately 
reports a drug stock out. He observed thus:  “these [anti-TB] drugs ….of course they don’t 
supply us with [anti-TB drugs] … they supply but in small quantities” (R8-02). Another one 
was more emphatic saying “We have the knowledge, we have identified the patient, we have 
done everything but the drugs are not there” (R4-01). Although stock outs were attributed to 
failure to deliver adequate quantities, some respondents admitted that they sometimes did not 
request adequate quantities.  
78 
 
Besides anti-TB drugs, stock outs were also observed for laboratory reagents leading 
to suspension of testing until reagent supplies were restored. Often this involved borrowing 
from other facilities, in which case patients would wait for hours to days. Alternatively, 
patients would be referred to other HFs, which equally prolonged the process of establishing 
disease diagnosis. A clinician team leader noted that:  
Hmm sometimes you can request for a sample, you find may be you have no slides. That 
patient is likely to wait, may be you give him or her the next appointment until when the 
slides are back. Sometimes the stains ah you find that the stain are not there ah sometimes we 
run out-stocks on drugs. So that patient may spend an hour or even two hours because you 
might not be having the drugs right now but you go to requisition from another facility. So it 
may take an hour or two hours like that. (R8-03) 
Often patients were told to wait as they searched elsewhere within the HF or at neighboring 
health facilities. One such respondent who had had the experience of searching around the 
health facility without success remarked that:  
Drugs, stock supplies because these days there are issues when the patient is in front of you 
and you have no drugs you check all other places there are no drugs and it is so 
demoralized…the patient gets so much demoralized and says now am dying if [hospital] 
doesn’t have the drug then am finished (R9-03) 
In some cases, they borrow from neighboring facilities. A respondent from a health facility 
which often borrowed reagents noted that “To make sure that the reagents are provided. Now 
when it comes to the point of [testing] if the reagents are not enough this person [lab 
assistant] will have to walk around look for which facility that can help to have the reagents 
where ever they are” R2-03. Sometimes patients were either given a return appointment 
when drugs and other supplies are expected to have been delivered or were referred to HFs 
where supplies are known to be adequate. One respondent noted that “Early January, we 
79 
 
were referring them to our sister hospitals because we can’t keep them here when they need 
treatment. So we could refer to them to …… nearby hospitals”.  
So just as much as there were mitigation measures against lack of TB drugs and basic testing 
supplies they often involved  patients waiting for long times or rescheduling procedures, 
which exacerbated delays 
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DISCUSSION  
QUANTITATIVE COMPONENT (AIMS 1&2)  
This study assessed how health service-related factors affected time taken to establish 
a diagnosis of TB and start treatment after a patient presented for consultation. Our findings 
show that there are opportunities to prevent delays in the TB care process. This study shows 
that 75% of patients’ treatment was initiated within three days. Though this compares 
favorably with five days in Zimbabwe (Takarinda et al, 2015) and six days in Ethiopia 
(Dimissie et al, 2002), a three-day window in our study points to missed opportunities to 
diagnose and treat TB on a patient’s first HF visit. The World Health Organization 
recommends same day laboratory TAT and treatment initiation if a positive result is reported 
(Davies et al, 2011). We found that HF level delays resulted from factors surrounding the TB 
testing processes and was independent of a HF’s structural characteristics. Therefore, care 
processes, and by extension quality of existing TB services, must be streamlined to eliminate 
HF level delays that may frustrate patients who seek care with TB symptoms.  
Association of service delivery factors with laboratory turnaround time  
Only two-fifths of TB test results were reported on the day a patient submitted a 
specimen suggesting most patients made at least two HF visits before receiving TB test 
results. Patients receiving TB test results two or more days after submitting a specimen has 
previously been found by other researchers where delay was attributed to use of a centralized 
laboratory system prolonging turnaround time (Claassens et al, 2013). Our study excluded 
patients diagnosed at an external laboratory and still showed delays suggesting that there are 
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inefficiencies in the onsite TB testing process. Knowing that most patients had two or more 
TB tests, it is possible specimens were being tested in batches after all required specimens 
have been submitted. Only 6.2% of our study patients required a repeat test after an index 
negative result. Therefore, unnecessary repeat laboratory visits and hence TAT can be 
reduced substantially if TB test results are reported the day the patient first visits a laboratory 
for testing.   
We found that length of laboratory TAT was independent of HF structural 
characteristics. There were no differences by ranking of a HF within the health system 
hierarchy and nor were there differences by HF ownership or number of laboratory 
personnel. Previous studies have focused mainly on how these structural factors were 
associated with TB testing in terms of whether a TB test is available onsite or not, and 
bottlenecks in ordering tests  (Belay et al, 2012; Buregeya et al, 2013; &Yimer et al, 2003). 
In Uganda, higher level HFs by design have more and better trained laboratory personnel 
than those at lower level ones. This numerical and skills advantage should translate into a 
shorter TAT. But these HFs also have a higher patient load and hence the personnel to work 
volume ratio result in similar wait times across all HF levels.  In addition, it appears in-
service training on TB testing has narrowed the skills gap between personnel between 
smaller and larger HFs.  
Our findings demonstrate a weekend effect on TAT of TB tests. Patients tested for 
TB on a weekend had a longer TAT than those tested during weekdays. A weekend effect in 
TB care has not been studied before. Evidence that quality of health care declines outside of 
business hours has previously been reported in studies involving in-patient treatment and 
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reported in terms of adverse disease outcomes (Bray et al, 2016; Aldridge et al, 2016). In 
Uganda, it is mandatory that all services, including outpatient ones, are available even on 
weekends.  However, it is possible that on weekends, TB testing is not a priority since 
patients are unlikely to present as emergencies requiring urgent attention. TB testing being an 
outpatient procedure, our study finding suggests that a weekend effect applies to both in-
patient and outpatient care. Further research involving interviews with weekend staffs or 
patient simulations could help us understand factors underlying the weekend effect.    
 Interestingly, retesting for TB prolonged TAT following an index test was negative 
but had no effect when it was positive. Uganda’s national TB care protocol recommends 
collection and testing of a second sample a day after the index test (MoH, 2017b). The 
procedure for retesting, including timing of specimen collection, does not depend on the 
index TB test result. It is possible there is more urgency to repeat a TB test if the index result 
is positive than when it is negative.  But also our study had a major limitation of not having a 
provision for recording results date in the laboratory register, and instead relied solely on the 
treatment register to compute TAT. The date in a treatment register is likely to correspond to 
a specific positive result based upon which treatment is started, and not for each test done for 
a patient as part of evaluation for the disease. This makes TAT for patients initially testing 
negative to appear longer since intervening periods when from negative results were not 
recorded. On the one hand, those retesting following a positive result may have the date of 
this result recorded even as they await a repeat result. Relative to the lab visit date, TAT is 
essentially timing of a positive result, not a true duration of each TB test. Provision for a 
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results date in the laboratory register is necessary to improve accuracy of lab TAT since this 
will capture information by each individual test.  
Association of service delivery factors with treatment initiation time  
 We found that 75% of the TB patients started treatment within one day of results 
reporting showing most patients had prompt initiation of treatment.  This contrasts with 
findings in Ethiopia (Belay et al, 2012), Ghana (Lawn et al, 1998) and China (Xu et al, 2013) 
where 75% treatment initiation was reached after 4, 14 and 73 days respectively. Only in 
Mozambique was treatment initiated in three days (Saifodine et al, 2013), In our study, it is 
apparent that once a positive TB result was reported, most patients start treatment, having 
waited until results were reported or the system was being efficient at  tracking patients with 
positive results and initiating them on treatment. 
 We observed that health facilities structural characteristics had no statistically 
significant effect on TxIT suggesting that actions taken to trace newly diagnosed patients and 
start them on treatment were similar regardless of HF size, location, ownership or even 
laboratory staffing. Prolonged TxIT has previously been described in the context of lacking 
extra personnel to trace patients upon receipt of TB test results from an external laboratory 
(Claassens et al, 2013); unlike in our study where both diagnosis and treatment were onsite. 
In another study involving structural factors, a longer TxIT in private HFs compared to 
public ones was attributed to patients in the former having to wait until guidance on drug 
regimens, dosage and other treatment decisions were obtained from the latter (Belay et al, 
2012). In our study setting, opportunities for training and ongoing technical support have 
penetrated all HFs equally. Having a nationally mandated treatment protocol has ensured 
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standardized approaches to treatment initiation. There was a significantly lower TxIT in 
Kyenjojo compared to other districts pointing to a better coverage of these capacity building 
interventions.  
 Patients diagnosed by Gene Xpert test had a longer TxIT than those tested by 
microscopy suggesting operational challenges in using the Gene Xpert technology. A similar 
finding with use of Xpert technology has previously been reported in a centralized laboratory 
setting (Cohen et al, 2015; Page et al, 2016). Here a return visit to receive TB results was 
mandatory and therefore TxIT depended on a patient returning as scheduled and the HF 
having adequate default reminder systems. When results were not returned as scheduled, 
patients may give up after repeated HFs visits to get results (Claassens et al, 2012). Since all 
our study patients were diagnosed and treated at the same facility, we expected identical 
treatment initiation procedures between the two diagnostic approaches.  Notable in this study 
is that Xpert sites serve as referral laboratories services for surrounding facilities and as such 
have a higher work load than those only providing microscopy. The resulting increase in wait 
time and hence prolonged TAT means these patients are more likely to require multiple visits 
before they receive results and start treatment. Therefore, it is important to put in place a 
system to absorb the additional samples brought from surrounding HFs.  
Association of service delivery factors with treatment delay 
In this study, 25% of the patients experienced treatment delay of more than two days 
having had a prolonged TAT and /or TxIT. This compares favorably with a rate of 31% that 
was reported in Zimbabwe even after a longer cut off threshold of four days was used 
(Takarinda et al, 2015). However, it is also possible that a higher rate in the reference study 
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was due to some patients being tested at external laboratories. Nonetheless, our finding still 
suggests the need to reduce delays. The current recommendation is for each presumptive TB 
patients to be tested and, if positive, commence treatment on the same day the patient   
presents for consultation (Davies et al, 2011). We selected a two day cutoff to accommodate 
patients who had an index negative result and needed an additional test to establish a 
positive TB diagnosis. Thus, much effort is needed to reduce delays knowing that with 75% 
of patients beginning treatment in three days, we are still far from achieving what is 
currently recommended.  
Notably, health facility size (level with in health system hierarchy), ownership and 
laboratory staffing did not affect treatment delay. Previous studies have reported that public 
and higher-level HFs had less delays compared to private and lower-level HFs (Getnet et al, 
2017). Underlying reasons for these differences were relatively poor TB care knowledge and 
skills among health care professionals at lower level HFs and private ones (Takarinda et 
al,2013; Buregeya et al 2013). Uganda has a standardized TB treatment protocol suggesting 
that knowledge and skills should not differ by healthcare facility structural characteristics. 
Also it is possible that small size HFs that typically have low staffing also had low patient 
volumes allowing for an appropriate patient to staff ratio regardless of HF size. None of the 
facilities in our study were private for profit HF, which limits our ability to compare private 
and public HFs. Thus, a better conclusion about structural characteristics could be drawn if 
the inclusion of a better representation of private for-profit HFs that are often small clinics 
and dispensaries. 
86 
 
Use of Gene Xpert technology still faces operational challenges since patients 
diagnosed by Gene Xpert testing had higher odds of delays than those tested by microscopy. 
Concerns with use of Gene Xpert have mainly been from centralized laboratory settings 
where delays were attributed to long TAT for results from the referral laboratory coupled 
with inefficient systems for tracing patients to start treatment (Takarinda et al, 2015;Cohen 
et al, 2015; Page et al, 2016). Though we excluded patients that received an Xpert test from 
an external laboratory, it is important to note that HFs with Xpert machines in Uganda also 
serve as referral laboratory services to surrounding facilities on top of processing specimens 
collected on site. As such TB test work volume was relatively higher at HF with Gene Xpert 
than those with microscopy, which may prolong TAT. Under such circumstances delays 
were due to failure to absorb extra workload associated with an Xpert site serving external 
patients. 
We also found that retesting for TB increased delays irrespective of the initial test 
result. It appears there are no studies evaluating the effect of retesting on TB treatment 
delay. It is not surprising patients with a negative index TB test result has a treatment delay 
since they must make additional visits before being eventually diagnosed. Among those 
whose index test was positive, it appears initiation of treatment was done mostly after they 
have received a second TB test result. The national TB treatment protocol recommends 
commencing treatment for any one positive test result (MoH, 2017a). Given only 6% of the 
patients had an index negative result, most patients should have commenced TB treatment 
after the index test. Therefore, preventing unnecessary repeat TB testing could go a long 
way in reducing treatment delays.  
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We found being tested on a weekend increased odds of treatment delay suggesting 
inefficiencies in TB care processes at this time of the week. Studies reporting weekend 
effect are mainly from inpatient and emergency room settings, and report differences in 
outcomes (Bray et al, 2016; Aldridge et al, 2016). Here outcomes being worse on weekends 
was attributed to delays in responding to needs of inpatients.. An observation of a weekend 
effect in our study is evidence that while TB services were available throughout the week, 
there were missed opportunities to identify and manage presumptive TB cases. However, 
there appears to be less dedication to caring for presumptive TB cases compared to other 
tasks on weekends. Qualitative interviews comparing patients presenting on a weekday to 
those seen on weekends would clarify how timing of the lab visit translates into treatment 
delay.   
In summary, our study shows there are delays even after a presumptive TB patient 
presented to a one stop center for diagnosis and treatment. There were opportunities for 
patients to receive TB test results and have appropriate care decisions taken promptly. 
Independent predictors of delay were being tested on a weekend, being diagnosed at a site 
where primary diagnostic technology was Gene Xpert, and non-adherence to the TB testing 
protocol. Health service factors related to structural characteristics of the health care facility 
did not affect the extent of TB treatment delay. However, a lot more on how these factors 
are associated with treatment delay can be learned from observation and time motion studies 
to examine TB care processes. 
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QUALITATIVE COMPONENT (AIM 3)  
The study sought to understand practices among healthcare workers that lead to 
delays in initiating TB patients on treatment. We found a big knowledge - action gap about 
recommended practices in the diagnosis and /or initiation of TB treatment. Healthcare 
workers understood that presumptive TB cases had to be identified and given priority over 
other patients, but this was not implemented consistently. Care decisions were often deferred 
awaiting designated personnel to sanction them. In addition, TB testing had a separate time 
schedule, often off-peak hours, which prolonged TAT for TB results compared to other 
laboratory services. Accordingly, trained healthcare workers must be supported to put 
acquired knowledge into practice.  
We found that individuals with TB symptoms often waited in queues alongside other 
patients showing that triage and fast tracking of presumptive TB cases was not being done 
consistently. Under these circumstances, TB patients must wait a long time before they are 
assisted or be forced to defer care, thereby hindering timely diagnosis of TB. This is 
consistent with findings of presumptive TB patients waiting in long queues at OPD, 
laboratory and even at dispensing windows in Uganda (Buregeya et al, 2013) and Malawi 
(Chimbatata et al, 2017). Here lack of consistent triaging was attributed to lack of staff 
dedicated to attending to TB patients, inadequate space for isolating presumptive TB patients 
and healthcare workers not understanding how this ultimately prevented disease 
transmission. In our study, we found that community volunteers reminded HF staff to attend 
to presumptive TB cases, which highlights the need for staff dedicated to TB patients. 
Without a dedicated team, HF staff will always be faced with competing priorities and hence 
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inefficiencies in the triage process. On the other hand, it is possible that triage protocols were 
simply ignored due to a perceived need to be fair to all waiting patients.  
We found that TB testing was done at a specific time, usually during off peak hours, 
which suggests lack of integration of TB testing into routine laboratory services. It appears 
existence within a HF of a TB test schedule parallel to that of other laboratory services has 
previously not been reported. Uganda’s TB treatment protocol does not explicitly 
recommend turnaround of a TB test result. But such institutionalized schedules mean that TB 
specimens were tested in batches and therefore patients must wait until late in the day or 
make a return visit to receive TB test results. Laboratory personnel felt this minimized the 
number of times they were exposed to infectious specimens and eliminated time loss that 
comes with elaborate clean up required after each TB test. It is also possible that a separate 
time schedule is a strategy to deal with heavy specimen volumes knowing that TB treatment 
guidelines do not emphasize urgency of TB over other laboratory tests. Therefore, fully 
integrating TB testing into routine laboratory services requires addressing the above concerns 
as well as recommending TB test TAT.   
Our findings suggest that care decision making also delayed TB treatment. Patients 
identified at triage had to be reviewed by a clinician before they were sent to the lab, which 
prolonged wait times. Furthermore, in some HF only designated personnel could initiate TB 
treatment. We did not come across literature highlighting bottlenecks associated with waiting 
for second opinion or designated personnel before sanctioning a TB care procedure. In 
Uganda, all TB care procedures have accompanying decision support tools that are simplified 
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for use by all cadres of healthcare workers. Accordingly, there was a need to train and 
support more staff to participate in providing TB care.   
Interestingly fear of contracting TB motivated healthcare workers to get involved in 
TB care as much as it shaped a negative attitude towards TB among others. The more 
healthcare workers fully appreciated they were at higher risk than the general population, the 
more they got involved in providing TB services. Existing literature largely associates fear of 
contracting TB among healthcare workers with discrimination of presumptive cases 
(Chimbatata et al, 2017; Buregeya et al, 2013). A study in Russia reported that fear of 
passing infection to loved ones did motivate healthcare workers to attend to TB patients 
(Woith et al, 2012). In our study, linking TB treatment to reduction of transmission to 
themselves and their families as well as other patients motivated healthcare workers to attend 
to TB patients. Healthcare workers are inevitably exposed to TB, due to frequent interaction 
with patients with undiagnosed and potentially contagious TB. Given HFs do not have 
dedicated staff to handle TB care tasks, getting more healthcare workers to take on the 
additional task of TB care will need to be centered on improving risk perception.  
This study suggests there was no discrimination against TB patients. Further, 
healthcare workers attending to TB patients did not experience courtesy stigma. Though 
reports of courtesy stigma are limited, discrimination amongst TB patients has been reported.  
A study in Malawi reported discrimination of TB patients was mainly because of fear of 
acquiring infection while attending to them (Chimbatata et al, 2017). It appears fear of 
contracting TB did not influence attitude towards TB patients and to those attending to them. 
We found that fear of being infected was heightened by perceived lack of personal protective 
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measures. Therefore, it is possible that discrimination against TB patients and health workers 
attending to them was lessened by availability of protective measures. But it is also possible 
that this positive finding was because our respondents being involved in TB care and already 
had a positive attitude to TB patients.  There could also have been social desirability bias 
since our findings were not corroborated by observation of TB care processes at study sites. 
A better approach to confirm this finding would be to conduct observations along with 
interviews.  
This study demonstrates that lack of appropriate knowledge and skills was both a 
genuine explanation as well as an excuse for health workers not promptly attending to TB 
patients. We learnt that some trained staff avoided TB care tasks and yet some that were not 
trained did not. This contrasts with studies on failure to implement TB infection control 
measures that make no reference to use of excuses by healthcare workers to avoid attending 
to TB patients (Woith et al, 2012; Buregeya et al, 2014).  In Uganda, HFs hold continuing 
medical education sessions during which staff(s) returning from trainings share acquired 
knowledge and skills with the rest. Accordingly, non-participating staffs were seen more as 
giving excuses than expressing genuine lack of knowledge. 
In summary, expressed knowledge of measures to prevent delays were not 
accompanied by appropriate practices. TB care processes were characterized by patients 
waiting in queues alongside general patients and a parallel test schedule, which prolonged 
turnaround times. Identified presumptive TB cases had to wait for a second opinion before 
ordering a TB test and there was lack of contingency measures to deal with staff absences. 
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Key barriers to timely diagnosis of TB were negative attitude among healthcare workers and 
understaffing. 
 Despite the above findings the study has several limitations. All respondents reported 
were actively participating in providing TB care, which could have overrepresented a 
positive rating of existing services given there was no comparison group.  The study did not 
verify by observation or other objective tests some of the findings especially positive ones. 
Using key informant interviews, it is possible that respondents reported socially desirable 
practices.  
STUDY SUMMARY AND IMPLICATIONS 
This study shows how critical efficiency of laboratory services is to initiating TB 
treatment. Health service-related factors that were associated with increased risk of TB 
treatment delay, which were use of Gene Xpert test technology, being retested during the 
course of diagnosis, and undergoing a TB test on a weekend, were all laboratory related.  A 
qualitative component helped highlight healthcare workers’ perspective about the adoption 
and implementation of efficacious TB care protocols. Existing records present a cheaper 
option of data collection compared to other methods given records abstraction is cheaper and 
less time consuming than other data collection approaches. This study examined patient 
records from many HF across different levels and therefore findings can be generalized to 
most primary care settings. Restricting the study to only HFs continuously providing TB 
services offers a window into quality gaps that may undermine the translation of expanding 
access to TB services into improved disease control. Such gaps resulting in delays are 
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essentially missed opportunities to treat TB early and prevent transmission. These study 
findings therefore contribute to finding ways to reduce the TB burden.  
The study however has a few limitations. Time is measured in days instead of hours 
or minutes which would have given a better resolution and hence detect more variation than 
we observed.  In measuring total treatment time, we assumed every patient was identified and 
tested for TB on the same date he/she first sought consultation at the HF. Using initial 
consultation as a start point and therefore including the screening stage in computing total 
time and helps determine if upstream processes before visiting the laboratory have an effect 
on delays.  Existing TB care records used for this study contained few sociodemographic 
variables, which limited the number of patient characteristics and hence confounding 
variables that could be controlled for during analysis. There were no records of such 
variables as a distance to the health facility, income and occupation that have been reported 
to increase delays (Storla et al, 2008; Gettnet et al, 20017). A study that supplements existing 
records with interviews of TB patients and clinical notes can help narrow this gap.  
By only enrolling TB patients that were eventually started on treatment, study 
findings may not be generalizable to all presumptive TB cases. Knowing that only 8-10% of 
presumptive TB cases test positive for TB (Chang et al, 2012), any difference between these 
and those that were negative results will surely undermine validity and hence external 
validity of study findings. Finally, findings from the interviews were not verified by 
observation and other objective measures, which introduces social desirability bias. Random 
selection of respondents would have minimized this but that staff interviewed typically had 
been on the frontline before moving to supervisory role. Since interviewees were in 
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leadership positions, they could have been motivated to portray a positive picture of TB care 
processes. Addressing the above limitations requires complementary data sources, which 
calls into consideration discussion of which one approach cross cuts across most of the 
limitations.   
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APPENDICES 
Appendix 1: Data abstraction form 
 
 
 
 
Study subject’s name ___________________________________study ID  
Health facility name ______________________________________ 
Date of data collection______/_______/__________ 
Research assistant’s name___________________________________ 
Part 1: Patient data abstraction form 
Laboratory register  
1. Age:_______ years 
2. Gender  
 
Male   
Female  
3. HIV status  
 
4. Date of sputum specimen submission (dd/mm/yyyy): _____/_____/________ 
5.  Does the specimen submission date fall on a weekend (Friday, Saturday or Sunday)? 
 
 
 
 
 
 
 
 
Positive  
 
Negative   
Unknown  
 
Yes  
 
No  
 
Unknown  
Study site 
code______________ 
Study participant 
code________ 
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6. Number of specimens tested: __________ specimens  
Tick that applies 
Scenario  Smear results  NAAT  
e.g. Gene Xpert 
Number 
of specimens tested 
1 +   1 
2 - +  2 
3 + +  2 
4   + 1 
5 - - + 3 
6 + + + 2 
7 - + + 2 
     
7. Sputum test results ( write 999 to indicate no results) 
Specimen 1______________________ 
Specimen 2_______________________ 
Specimen 3_____________________ 
Specimen 4 ____________________ 
8. Number of specimens tested to establish diagnosis 
 
  
 
9. Type of test(s) conducted (circle all that apply) 
 
 
Comments: ____________________________________________________________________ 
Unit TB register 
10. District TB number  
11. TB treatment start date: _____/_______/_______ (write 999 if information is missing) 
12. Results reporting date: _____/_______/_______  (write 999 if information is missing) 
 
 
 1 specimen (scenarios 1&4) 
 2 or more specimens following an initial negative result (scenarios 2,5&7) 
 2 or more specimens following an initial positive result (scenarios 3&6) 
 
Microscopy  
 
Gene Xpert test  
 
Other(specify)___________________  
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13. Was patient diagnosed at a time the health facility had a stock out of anti-TB drugs? 
 
 
 
14. Write TB type (disease class) indicated in the register ____________ 
15. Has patient been treated for TB before this current episode? Check for type of TB 
 
Yes  
 
No 
Out –patient department register 
16. What was the date of the first visit the patient made in the 14 days prior to diagnosis? 
______/______/________ (write 999 if information is missing) 
17. How many visits including that of the specimen submission date, were made prior to testing of 
first sample?_____________(write 999 if information is missing) 
 
 
18. Please indicate treatments received on all visits including the dates when patient visited health 
facility and when a TB specimen was submitted for testing. Write 999 if information is missing  
Date of facility visit  Diagnosis  Treatment given ( drugs) 
______/______/________   
______/______/________   
______/______/________   
______/______/________   
19.  Did the patient receive antibiotics on any of the above visits?  
 
 
Yes  
 
No  
 
Unknown  
 
Yes  
 
No   
Unknown  
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Part 2: Health facility data 
20. Location of Health facility (name of the district) _________________________ 
21. Health facility ownership  
 
 
 
 
22. Level of facility within health system hierarchy 
 
 
 
 
Laboratory services 
23. Count the unduplicated number of trained laboratory personnel (assistants, technicians and 
technologists) from the laboratory duty roster?  __________ 
24.  What equipment is available for TB testing at this Health facility? tick all that apply 
 
 
 
25. What laboratory TB tests are available to patients at this healthcare facility upon sample referral? 
 
 
26. Are all registers covering the study period January 1st, 2016 to December 31st, 2017 available? 
Please indicate in the comments section the dates for which registers are missing  
Register  Are all registers 
available?   
Comments ( indicate dates for which registers are 
missing) 
Lab register    
TB unit register    
OPD register   
 
 
Publicly owned  
 
Private not for profit 
 
Private for profit  
 
Health center III  
 
Health center IV 
 
Hospital  
 
 
Microscope  
 
Gene Xpert machine   
 
Others (specify)___________________  
 
Fluorescent microscope  
 
Gene Xpert machine   
 Culture  
 
Others (specify)___________________  
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27. In the lab register, count the number of patients that were tested for TB in the following time 
periods. Exclude those indicated as follow up   
Period  Total tested  Total sputum positive  
Jan 1st – Mar 31st, 2016   
Apr 1st – Jun 30th ,2016   
Jul 1st – Sep 30th, 2016   
Oct 1st – Dec 31st,2016   
Jan 1st – Mar 31st, 2017   
Apr 1st – Jun 30th ,2017   
Jul 1st – Sep 30th, 2017   
Oct 1st – Dec 31st,2017   
Total    
 Average quarterly number of cases diagnosed__________  
28. Ask health facility TB focal person: How many times did the healthcare facility experience a 
stock out of anti-TB drugs in the period January 1st, 2016 to December 31st, 2017? 
___________________ 
29. Document periods of  stock outs of TB drug ( record dates when levels of any of  the TB drugs 
(RH or EH or RHZE) were recorded as zero on the stock card)  
From  To  Drug name(s) 
_____/_____/______ _____/_____/________ ______________________ 
_____/_____/______ _____/_____/________ ______________________ 
_____/_____/______ _____/_____/________ ______________________ 
_____/_____/______ _____/_____/________ ______________________ 
_____/_____/______ _____/_____/________ ______________________ 
_____/_____/______ _____/_____/________ ______________________ 
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Appendix 2: interview guide 
Interviewee data collection sheet 
 
Level of health facility: _____________________________________ 
Age: ________ years   
Gender of respondent: Male/Female   
Job designation: Laboratory in charge/ clinical team leader/ in-charge outpatient department  
Semi-Structured Interview guide 
1. Tell me how you came to be treating TB patients? 
2. What specific roles do you currently have in the diagnosis and treatment of TB? 
3. Can you please describe the detection and treatment process for TB patients in your 
facility? 
Probe:  
How is it done in the unit where you currently work? 
What happens in other units within this health facility that you collaborate with?  
What specific practices might contribute to delays after a patient has presented for 
consultation?  
What about your fellow staffs? What is it that they do that contributes to the time it 
takes to get diagnosed and treated for TB? 
4. What about the TB patients? How different are they from other patients that you see?  
Probe:  
Do these differences from other patients affect the way they are attended to? 
Do you have any concerns about treating TB patients? Do any of your colleagues 
have concerns about treating TB patients?  
How do other staff feel about those of you who treat TB patients?  
5. What needs to be done to get all TB patients tested for TB and treated on time?  
Probe:  
How much maximum time it should take to identify and treat a TB patient. 
What needs to be done to fast track TB services? 
Of what benefit is fast tracking TB services?   
6. Is there anything else that you would like to tell me about delays in treating TB patients 
that we have not discussed?  
 
Thank you for participating in this study 
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Appendix 3: Informed consent form 
 
University of Texas Health science center at Houston 
 
INFORMED CONSENT FORM TO TAKE PART IN RESEARCH 
HSC- -SPH-18-0264 
 
INVITATION TO TAKE PART 
 
You are invited to take part in a research project called Examining the effect of service 
delivery factors on timely initiation of tuberculosis treatment within primary care 
settings in Uganda (TB treatment delay study) conducted by Dr. Juma Michael of the 
University of Texas Health science center at Houston (UThealth). For this project he will be 
called the principal investigator.  
Your decision to take part is voluntary. You may refuse to take part, or choose to stop taking 
part, at any time. A decision to not take part or stop being part of the research project will not 
affect your work evaluation or any other aspect of your job. 
You may refuse to answer any question asked.  This research project has been reviewed by 
the committee for protection of human subjects of University of Texas Health science center 
at Houston as HSC- -SPH-18-0264. 
PURPOSE 
The purpose of the research study is to understand your perspective if there are delays in 
diagnosing and treating TB in terms of causes and ways to prevent delays if they occur. This 
research study looks at the time it takes to diagnose and treat TB after the patient has 
presented to a health facility providing the services. The interest is in understanding delays in 
identifying patients for TB testing, completing required tests and starting those with the 
disease on treatment. We would like to know what can be done to minimize delays. You are 
being invited to join this research. 
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PROCEDURES 
You have been selected to participate in this interview because of the critical role your unit 
plays in identifying and providing care to patients with TB symptoms. You play an important 
role in the diagnosis and treatment of TB within the health facility.    
If you agree and are able to participate in this study you will first sign a consent form before 
undergoing the interview. During the interview I will sit with you in a comfortable place at 
your place of work or any other location of your choice. This will be conducted during the 
working hours and interviews will therefore occur at a time when you can take a break from 
your work to be interviewed. Please feel free to let me know if you do not wish to answer any 
question and I will move to the next one. The interview will be audio-recorded in effort to 
capture responses during the interview. The tape will be kept in a locked cabinet in my office 
at school. The interviews will be deleted from the recorders once transcription is completed. 
The information is confidential and only my research supervisors and I will have access to it. 
No name of the responded or health facility will be recorded. 
TIME COMMITMENT  
Only a single interview will be conducted. It is planned that the interview will last 30-50 
minutes.  
BENEFITS 
There is no immediate direct benefit to you for your participation. Your participation will 
contribute to finding out how to treat TB early and prevent its transmission within health 
facilities and communities.  
RISKS AND /OR DISCOMFORTS 
There is no major risk associated with participating in this study. However, you may lose 
some work time since the interview will be conducted during business hours. The interview 
will be scheduled at a time when it is convenient to take a break off your work schedule to 
minimize lost work time. Also you may feel embarrassed or uncomfortable answering some 
of the questions. You may stop at any time or skip any questions.  During the interview, 
please feel free to seek for clarifications on interview questions and not answer those you 
find difficult or uncomfortable about.  
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 There is no anticipated risk that your personal information will be shared. The 
information that will be collected concerns how your facility is managing patients presenting 
with TB symptoms. The information the researcher collects will only have a number instead 
of your name. The health facility name will also be replaced by a number. Only the 
researcher will know your number and that of your health facility. This number will be kept 
locked up in a filing cabinet and can only be accessed by the principal investigator and 
research supervisors.  
Nonetheless you do not have to answer a particular question or take part in the interview if 
talking about a particular topic makes you uncomfortable.  
STUDY WITHDRAWAL 
Your participation in this research study is entirely voluntary. You can choose to participate 
or not. Participating or not will not affect your job or work evaluation in any way. You may 
also stop participating in this study at any time. This will not put you at a disadvantage in 
anyway. In event that you withdraw from the study, all information so far collected about 
you will be discarded and therefore none of it will be used. 
COST, REIMBURSEMENTS AND COMPENSATION 
If you decide to take part in this research study, you will not incur any additional costs. You 
will not be provided money or any other type of incentive for participating in this study. 
Sharing the Results 
The results of the study will only be published in journal articles as a whole so that there will 
be no way of knowing your name or that of your health facility and district. The knowledge 
will be shared with health sector planners, academia and the public through publications in 
journals so that other people can learn from the research.  
CONFIDENTIALITY 
You will not be personally identified in any reports or publications that may result from this 
study.  
Please understand that representatives of the, the University of Texas Health Science Center 
at Houston, the sponsor of this research, and/or companies engaged with UTHealth for the 
commercialization of the results of the study may review your research and/or medical 
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records for the purposes of verifying research data, and will see personal identifiers.   You 
will not be personally identified in any reports or publications that may result from this study. 
There is a separate section in this consent form that you will be asked to sign which details 
the use and disclosure of your protected health information. 
QUESTIONS 
This research study has been approved by the committees that are responsible for protecting 
people participating in research from harm in Uganda It has also been approved by the 
University of Texas Committee for protection of human subjects (CPHS).  
If you have questions at any time about this research study, please feel to contact the 
following as they will be glad to answer your questions: 
The principal investigator, Dr. Juma Michael on +256770898832 
Dr. Jesse Kagimba, M.D., M.Sc. 
Chairman IRB/REC, 
Joint Clinical Research Centre, 
Lubowa Hill, 
Plot 101Entebbe Road 
P. O. Box 10005, 
Wakiso District, Uganda. 
Tel: +256 417723000 
Cell: +256 712 531 656/+256 706 300 
300 
University of Texas Committee for the 
Protection of Human Subjects 
6410 Fannin, Suite 1100 
Houston, Texas 77030 
Phone +1713-500-7943 
Fax     +1713-500-7951 
Email cphs@uth.tmc.edu 
 
 
You can also contact the study team to voice your concerns, discuss problems, obtain 
information, and offer in put in addition to asking questions. 
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SIGNATURES 
 
Sign below only if you understand the information given to you about the research and you 
choose to take part. Make sure that any questions have been answered and that you 
understand the study. If you have any questions or concerns about your rights as a research 
subject, call the Committee for the Protection of Human Subjects at (713) 500-7943. You 
may also call the Committee if you wish to discuss problems, concerns, and questions; obtain 
information about the research; and offer input about current or past participation in a 
research study. If you decide to take part in this research study, a copy of this signed consent 
form will be given to you. 
 
     
Printed Name of Subject  
 
 Signature of Subject   Date               
 
     
     
 
 
Printed Name of Person 
Obtaining Informed 
Consent 
 
 Signature of Person 
Obtaining Informed 
Consent 
 Date               
 
 
 
CPHS STATEMENT: This study (HSC-SPH-18-0264) has been reviewed by the 
Committee for the Protection of Human Subjects (CPHS) of the University of Texas Health 
Science Center at Houston. For any questions about research subject's rights, or to report a 
research-related injury, call the CPHS at (713) 500-7943. 
Date______/_____/_________   
 
 
 
